睿知中国疾病研究地图
候选清单0

郑州郑州大学

郑州大学第一附属医院

First Affiliated Hospital of Zhengzhou University

在本站收录的 53 种疾病中,这家医院列在其中 39 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

郑州大学第一附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma15 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma79 篇牵头论文牵头 6 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma169 篇牵头论文牵头 2 项开放试验
  4. 胃癌Stomach cancer105 篇牵头论文牵头 5 项开放试验
  5. 肝母细胞瘤Hepatoblastoma2 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma5 篇牵头论文
  7. 脊索瘤Chordoma0 篇牵头论文
  8. 骨肉瘤Osteosarcoma33 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour8 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma15 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma3 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma15 篇牵头论文
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia1 篇牵头论文牵头 1 项开放试验
  14. 再生障碍性贫血Aplastic anaemia9 篇牵头论文
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis3 篇牵头论文
  16. β 地中海贫血Beta thalassaemia0 篇牵头论文
  17. 血友病 AHaemophilia A3 篇牵头论文
  18. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  19. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder11 篇牵头论文
  20. 重症肌无力Myasthenia gravis4 篇牵头论文
  21. 烟雾病Moyamoya disease10 篇牵头论文
  22. 肝豆状核变性Wilson disease1 篇牵头论文
  23. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis9 篇牵头论文
  24. 大动脉炎Takayasu arteritis0 篇牵头论文
  25. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  26. 特发性肺纤维化Idiopathic pulmonary fibrosis12 篇牵头论文
  27. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis0 篇牵头论文
  28. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis5 篇牵头论文
  29. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  30. 法布雷病Fabry disease0 篇牵头论文
  31. 庞贝病Pompe disease0 篇牵头论文
  32. 杜氏肌营养不良Duchenne muscular dystrophy6 篇牵头论文
  33. 白塞病Behçet disease9 篇牵头论文
  34. Alport 综合征Alport syndrome0 篇牵头论文
  35. IgA 肾病IgA nephropathy35 篇牵头论文
  36. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  37. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  38. 先天性巨结肠Hirschsprung disease0 篇牵头论文
  39. Leber 遗传性视神经病变Leber hereditary optic neuropathy2 篇牵头论文

未列出的收录疾病:非典型溶血性尿毒症综合征、范可尼贫血、IgG4相关性疾病、胆道闭锁、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.6%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 5520222023: 3320232024: 3320242025: 222025

郑州有 4 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题免疫治疗放疗技术副作用与生活质量
论文中的科室放疗科耳鼻喉/头颈外科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文15
  1. Alterations in nasal airflow and air conditioning after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: a pilot computational fluid dynamics study.2026Computer methods in biomechanics and biomedical engineering
  2. Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.2025Annals of medicine免费全文
  3. The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.2025PloS one免费全文
  4. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer.2024Cancer medicine免费全文
  5. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.2024Histology and histopathology
  6. How enteral nutrition modes influence nasopharyngeal carcinoma survivors with late dysphagia after radiotherapy: a randomized controlled study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  7. The role of extracellular vesicles in the development of nasopharyngeal carcinoma and potential clinical applications.2023Cancer medicine免费全文
  8. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway.2023Cell cycle (Georgetown, Tex.)免费全文
  9. CircMAN1A2 contributes to nasopharyngeal carcinoma progression via enhancing the ubiquitination of ATMIN through miR-135a-3p/UBR5 axis.2023Human cell
  10. Tumor cell-derived exosome RNF126 affects the immune microenvironment and promotes nasopharyngeal carcinoma progression by regulating PTEN ubiquitination.2022Apoptosis : an international journal on programmed cell death
  11. Differentially Infiltrated Identification of Novel Diagnostic Biomarkers Associated with Immune Infiltration in Nasopharyngeal Carcinoma.2022Disease markers免费全文
  12. miR-339-3p inhibits cell growth and epithelial-mesenchymal transition in nasopharyngeal carcinoma by modulating the KAT6A/TRIM24 axis.2022International journal of clinical oncology
  13. Hyperthermia inhibits growth of nasopharyngeal carcinoma through degradation of c-Myc.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  14. Circular RNA ITCH attenuates the progression of nasopharyngeal carcinoma by inducing PTEN upregulation via miR-214.2022The journal of gene medicine
  15. Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.2021Experimental & molecular medicine免费全文
中文论文(未计入)1
  1. [Nasopharyngeal carcinoma with non-squamous immunophenotype: a clinicopathological analysis of 23 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Health Outcomes of Nasopharyngeal Carcinoma Patients Three Years After Treatment by the AI-assisted Home Enteral Nutrition Management已完成NCT06603909研究中心不分期2021-01 启动
PubMed 以外找到的论文(未计入)7
  1. Genistein and chlorin E6-loaded versatile nanoformulation for remodeling the hypoxia-related tumor microenvironment and boosting photodynamic therapy in nasopharyngeal carcinoma treatment2025Advanced Composites and Hybrid Materials论文
  2. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)预印本
  3. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  4. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figshare数据集
  5. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集
  6. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  7. Retraction Note: MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by downregulating LHX22021Journal of Experimental & Clinical Cancer Research撤稿

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 79 篇,占 2.7%。

牵头论文
79
2021–2025 年
牵头试验
18
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 131320212022: 232320222023: 101020232024: 151520242025: 18182025

郑州有 6 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
    分期
    II期
    开始
    2024-08
    登记号
    NCT07016724

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  2. 正在招募
    Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
    分期
    II期
    开始
    2023-03
    登记号
    NCT05738434

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  3. 正在招募
    Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2023-03
    登记号
    NCT06718205

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  4. 正在招募
    A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
    分期
    II期
    开始
    2022-01
    登记号
    NCT05182944

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  5. 即将招募
    A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2026-04
    登记号
    NCT07446335

    年龄 18 岁 至 未注明(登记的条件)

    牵头:郑州大学第一附属医院郑州

  6. 即将招募
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07769658

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院;另有 5 家列出的医院为研究中心上海、天津、广州、成都、昆明、郑州

  7. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  8. 正在招募
    A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-09
    登记号
    NCT07751341

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因免疫治疗新辅助与综合治疗
论文中的科室病理/检验科肿瘤内科放疗科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文79
  1. Comparison of single-port inflatable mediastinoscopic esophagectomy and thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.2025BMC cancer免费全文
  2. Oridonin combined with cisplatin synergistically induces apoptosis by activating the NOXA-BCL2 axis in esophageal squamous cell carcinoma.2025Biochemical pharmacology
  3. Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  4. SETD7-mediated H3K4me1 activates ALDH1A3 to drive ferroptosis resistance in esophageal squamous cell carcinoma.2025Cell death & disease免费全文
  5. CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1.2025Cellular & molecular biology letters免费全文
  6. NDC80 promotes epithelial to mesenchymal transition of esophageal squamous cell carcinoma through macrophages polarization and PI3K/AKT pathway activation.2025European journal of medical research免费全文
  7. Identification of CTSC-driven progression in ESCC by single-cell sequencing and experimental validation.2025Frontiers in immunology免费全文
  8. TGF-β-activated NK-92 cell therapy for esophageal squamous cell carcinoma.2025International immunopharmacology
  9. Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.2025Molecular cancer免费全文
  10. GPR87 Promotes Angiogenesis in Esophageal Squamous Cell Carcinoma via VEGFA Regulation.2025Molecular carcinogenesis
  11. LINC02154 Promotes Esophageal Squamous Cell Carcinoma Progression via the PI3K-AKT-mTOR Signaling Pathway by Interacting With IGF2BP2.2025Molecular carcinogenesis
  12. FKBP Prolyl Isomerase 11: A Novel Oncogene Interacting With SRSF1 in Esophageal Squamous Cell Carcinoma.2025Molecular carcinogenesis
  13. Triptolide reverses cis‑diamminedichloroplatinum resistance in esophageal squamous cell carcinoma by suppressing glycolysis and causing mitochondrial malfunction.2025Molecular medicine reports免费全文
  14. Targeting CDH11 with celecoxib and derivatives to suppress esophageal squamous cell carcinoma proliferation and invasion.2025Pathology, research and practice
  15. Dynamic landscape and regulation of m5C methylation in human tissues.2025Science China. Life sciences
  16. Survival Outcome of Thoraco-Laparoscopic McKeown Esophagectomy Versus Endoscopic Submucosal Dissection for Early-Stage Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.2025Thoracic cancer
  17. Ethnic genomic differences in esophageal squamous cell carcinoma: Whole-exome sequencing of Han and Kazakh populations in China.2025World journal of gastroenterology免费全文
  18. Circ_0001741 regulates proliferation and invasion in ESCC via the miR-194-5p/E2F3 axis.2025World journal of surgical oncology免费全文
  19. [Not Available].2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  20. PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA.2024Biology direct免费全文
  21. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.2024Bioorganic chemistry
  22. Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test.2024British journal of cancer免费全文
  23. A 18F-FDG PET/CT-based deep learning-radiomics-clinical model for prediction of cervical lymph node metastasis in esophageal squamous cell carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  24. Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1+ macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2024Cancer immunology, immunotherapy : CII免费全文
  25. A 70-Year-Old Man With an Encapsulated Mediastinal Fluid Collection.2024Chest
  26. Construction and analysis of protein-protein interaction network for esophageal squamous cell carcinoma.2024Computers in biology and medicine
  27. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.2024European journal of cancer (Oxford, England : 1990)
  28. Single-cell sequencing analysis reveals cancer-associated pericyte subgroup in esophageal squamous cell carcinoma to predict prognosis.2024Frontiers in immunology免费全文
  29. A novel link between circPDE3B and ferroptosis in esophageal squamous cell carcinoma progression.2024Genomics
  30. Exosome-transported of circ_0081069 induces SPIN1 production by binding to miR-195-5p to inhibit radiosensitivity in esophageal squamous cell carcinoma.2024Journal of biochemical and molecular toxicology
  31. Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study.2024Med (New York, N.Y.)
  32. The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma.2024Nature communications免费全文
  33. Clinical and genetic characteristics of patients with TRG 0 and TRG III in esophageal squamous cell carcinoma after neoadjuvant therapy.2024Scientific reports免费全文
  34. STAT3-EphA7 axis contributes to the progression of esophageal squamous cell carcinoma.2023Acta oncologica (Stockholm, Sweden)
  35. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell Carcinoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  36. Downregulation of miR-100-5p in cancer-associated fibroblast-derived exosomes facilitates lymphangiogenesis in esophageal squamous cell carcinoma.2023Cancer medicine免费全文
  37. USP8 inhibitor-induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma.2023Cell biology and toxicology
  38. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.2023Frontiers in immunology免费全文
  39. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.2023Frontiers in immunology免费全文
  40. Integration of IDPC Clustering Analysis and Interpretable Machine Learning for Survival Risk Prediction of Patients with ESCC.2023Interdisciplinary sciences, computational life sciences
  41. Long non-coding RNA HOXC-AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression.2023Journal of clinical laboratory analysis免费全文
  42. G2 and S phase-expressed-1 induces chromosomal instability in esophageal squamous cell carcinoma cells and inhibits cell apoptosis through ROS/JNK signaling.2023Molecular carcinogenesis
  43. Expression significance of Emi1, UBCH10 and CyclinB1 in esophageal squamous cell carcinoma.2023Pathology oncology research : POR免费全文
  44. Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A.2022Analytical cellular pathology (Amsterdam)免费全文
  45. Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.2022Anti-cancer drugs免费全文
  46. ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells.2022Apoptosis : an international journal on programmed cell death
  47. Hsa_circ_0023984 Regulates Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cancer via Regulating miR-1294/PI3K/Akt/c-Myc Pathway.2022Applied biochemistry and biotechnology
  48. Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection.2022BMC medical genomics免费全文
  49. Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial.2022BMJ openRCT免费全文
  50. Long non-coding RNA NCK1-AS1 is overexpressed in esophageal squamous cell carcinoma and predicts survival.2022Bioengineered免费全文
  51. Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14.2022Bioengineered免费全文
  52. Similarities between wound re-epithelialization and Metastasis in ESCC and the crucial involvement of macrophages: A review.2022Cancer treatment and research communications
  53. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.2022Clinics and research in hepatology and gastroenterology
  54. Survival Prediction Model for Patients with Esophageal Squamous Cell Carcinoma Based on the Parameter-Optimized Deep Belief Network Using the Improved Archimedes Optimization Algorithm.2022Computational and mathematical methods in medicine免费全文
  55. Survival Risk Prediction of Esophageal Squamous Cell Carcinoma Based on BES-LSSVM.2022Computational intelligence and neuroscience免费全文
  56. Survival risk prediction model for ESCC based on relief feature selection and CNN.2022Computers in biology and medicine
  57. Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma.2022Cytotherapy
  58. Immuno-oncological role of 20S proteasome alpha-subunit 3 in aggravating the progression of esophageal squamous cell carcinoma.2022European journal of immunology
  59. Long non-coding RNA BBOX1-AS1 exacerbates esophageal squamous cell carcinoma development by regulating HOXB7/β-catenin axis.2022Experimental cell research
  60. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.2022Frontiers in immunology免费全文
  61. Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma.2022Journal of cellular and molecular medicine免费全文
  62. IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis.2022Journal of experimental & clinical cancer research : CR免费全文
  63. Serine 727 phosphorylation is necessary to induce the STAT3-mediated transcription of LINC00184 in oesophageal squamous cell carcinoma.2022Molecular and cellular biochemistry
  64. Antitumor Effects of Astaxanthin on Esophageal Squamous Cell Carcinoma by up-Regulation of PPARγ.2022Nutrition and cancer
  65. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.2022The lancet. Gastroenterology & hepatology
  66. Increased prognostic value of clinical-reproductive model in Chinese female patients with esophageal squamous cell carcinoma.2022World journal of gastroenterology免费全文
  67. Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.2021Aging免费全文
  68. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.2021Cancer letters
  69. Eomes promotes esophageal carcinoma progression by recruiting Treg cells through the CCL20-CCR6 pathway.2021Cancer science免费全文
  70. Circular RNA hsa_circ_0000277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression.2021Cell death & disease免费全文
  71. Inhibition of deubiquitination by PR-619 induces apoptosis and autophagy via ubi-protein aggregation-activated ER stress in oesophageal squamous cell carcinoma.2021Cell proliferation免费全文
  72. High serum superoxide dismutase activity improves radiation-related quality of life in patients with esophageal squamous cell carcinoma.2021Clinics (Sao Paulo, Brazil)免费全文
  73. Concomitant Expression of Inhibitory Molecules for T cell Activation Predicts Poor Survival in Patients with Esophageal Squamous Cell Carcinoma.2021Current cancer drug targets
  74. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.2021International immunopharmacology
  75. LINC00514 promotes lipogenesis and tumor progression in esophageal squamous cell carcinoma by sponging miR‑378a‑5p to enhance SPHK1 expression.2021International journal of oncology免费全文
  76. TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.2021Journal of experimental & clinical cancer research : CR免费全文
  77. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival in Esophageal Squamous Cell Carcinoma Patients.2021Nutrition and cancer
  78. Long non‑coding RNA CASC15 facilitates esophageal squamous cell carcinoma tumorigenesis via decreasing SIM2 stability via FTO‑mediated demethylation.2021Oncology reports免费全文
  79. Preoperative maximal voluntary ventilation, hemoglobin, albumin, lymphocytes and platelets predict postoperative survival in esophageal squamous cell carcinoma.2021World journal of gastroenterology免费全文
中文论文(未计入)5
  1. [Clinical Features and Prognosis of Multiple Myeloma Patients with Secondary Primary Malignancies].2023Zhongguo shi yan xue ye xue za zhiRCT
  2. [Study on the prognostic influencing factors of esophageal squamous cell carcinoma and the predictive value of inflammatory reaction indexes on its postoperative recurrence].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Clinical characteristics of 272 437 patients with different histopathological subtypes of primary esophageal malignant tumors].2022Zhonghua nei ke za zhi
  4. [The suppressive effects of microRNA-139-5p on proliferation and invasion of esophageal squamous cell carcinoma].2021Zhonghua yi xue za zhi
  5. [Establishment and validation of prognostic risk score model for esophageal squamous cell carcinoma based on immune related genes].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
  1. A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma即将招募NCT07446335牵头方III期2026-04 启动
  2. Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma即将招募NCT07769658牵头方2026-09 启动
  3. Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer正在招募NCT07016724牵头方II期2024-08 启动
  4. Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma正在招募NCT06718205牵头方II期2023-03 启动
  5. Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC正在招募NCT05738434牵头方II期2023-03 启动
  6. A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC正在招募NCT05182944牵头方II期2022-01 启动
  7. IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)状态不明NCT06078657牵头方II期2023-10 启动
  8. Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)状态不明NCT05896787牵头方II期2023-08 启动
  9. Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer状态不明NCT04654403牵头方不分期2022-01 启动
  10. Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)状态不明NCT05038813牵头方II期2022-03 启动
  11. Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03766178牵头方II期2021-09 启动
  12. A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC状态不明NCT04514835牵头方II期2021-12 启动
  13. Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma状态不明NCT04888403牵头方II期2021-12 启动
  14. The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC状态不明NCT03917966牵头方II期2020-04 启动
  15. A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03736863牵头方II期2019-12 启动
  16. Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma状态不明NCT03387904牵头方II期2019-01 启动
  17. A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC状态不明NCT03817658牵头方II期2019-10 启动
  18. Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03193424牵头方II期2016-10 启动
  19. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  20. A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma正在招募NCT07751341研究中心II期2026-09 启动
  21. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  22. Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma已终止NCT05834543研究中心I/II期2023-05 启动
  23. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  24. Clinical Study of Pan-cancer DNA Methylation Test in Plasma状态不明NCT05685524研究中心2022-07 启动
  25. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  26. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  27. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  28. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  29. A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)状态不明NCT03958890研究中心III期2019-06 启动
  30. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  31. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  32. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  33. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  34. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
  35. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial状态不明NCT02319187研究中心III期2014-12 启动
  36. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)72
  1. 022. TREATMENT EXPERIENCE OF ESOPHAGEAL FISTULA INDUCED BY NEOADJUVANT THERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-CENTER EXPERIENCE2025Diseases of the Esophagus论文
  2. 023. CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY FOLLOWED BY SALVAGE LYMPHADENECTOMY FOR RECURRENCE IN CERVICAL LYMPH NODES AFTER ESOPHAGECTOMY: A SINGLE-CENTER PROSPECTIVE STUDY2025Diseases of the Esophagus论文
  3. 024. CONVERSION ESOPHAGECTOMY FOLLOWING IMMUNOCHEMOTHERAPY IN UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-CENTER, PROSPECTIVE STUDY2025Diseases of the Esophagus论文
  4. 2131P Adebrelimab plus apatinib in advanced esophageal squamous cell carcinoma following immune checkpoint inhibitors: Preliminary results from cohort 3 of CAP 02 study2025Annals of Oncology论文
  5. Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2025Journal of Clinical Oncology会议摘要
  6. Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial.2025Journal of Clinical Oncology论文
  7. Functional characterization of GNA11 in esophageal squamous cell carcinoma: bioinformatics and cellular functional analysis2025ScienceAsia论文
  8. Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology2025Research Square预印本
  9. 442. POSTOPERATIVE ADJUVANT RADIOTHERAPY REDUCES LOCOREGIONAL RECURRENCE IN PATIENTS WITH BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagus论文
  10. 448. PREOPERATIVE PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY FOR THORACIC ESCC WITH CERVICAL LYMPH NODE METASTASIS (PICC-1): A PROSPECTIVE, PHASE 2 STUDY2024Diseases of the Esophagus论文
  11. 502P A novel miRNA pair biomarker of miR-1180-3p|miR-505-3p for predicting neoadjuvant chemoradiotherapy survival in esophageal squamous cell carcinoma: A multicenter study in China2024Annals of Oncology论文
  12. A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.2024Journal of Clinical Oncology会议摘要
  13. A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  14. Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  15. Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial.2024Journal of Clinical Oncology会议摘要
  16. Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.2024Journal of Clinical Oncology会议摘要
  17. Clinical pathological characteristics and expression of 328 proteins and their impact on survival in over 20,000 cases of esophageal squamous cell carcinoma and colorectal adenocarcinoma2024Chinese Science Bulletin (Chinese Version)论文
  18. Development of a new EGFR-VHH-CAR T-cell therapy for treatment of esophageal squamous cell carcinoma2024Research Square预印本
  19. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  20. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncology会议摘要
  21. SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  22. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncology会议摘要
  23. Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  24. Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  25. 1531P Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial2023Annals of Oncology论文
  26. 482. SECOND-LINE OF CAMRELIZUMAB PLUS NIMOTUZUMAB IN ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A SINGLE-ARM, OPEN-LABEL, PHASE 2 TRIAL2023Diseases of the Esophagus论文
  27. 487. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL2023Diseases of the Esophagus论文
  28. A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.2023Journal of Clinical Oncology会议摘要
  29. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  30. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  31. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  32. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  33. Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.2023Journal of Clinical Oncology会议摘要
  34. Anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer: Updated results from a retrospective real-world study.2023Journal of Clinical Oncology会议摘要
  35. Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.2023Journal of Clinical Oncology会议摘要
  36. Data from Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers2023未列出期刊其他
  37. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncology会议摘要
  38. Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.2023Journal of Clinical Oncology会议摘要
  39. Survival Prediction of Esophageal Squamous Cell Carcinoma Based on the Prognostic Index and Sparrow Search Algorithm-Support Vector Machine2023Current Bioinformatics论文
  40. Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.2023Journal of Clinical Oncology会议摘要
  41. 345. CAMRELIZUMAB AS ADJUVANT THERAPY IN RESECTED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL2022Diseases of the Esophagus论文
  42. 355. CAMRELIZUMAB COMBINED WITH CHEMOTHERAPY OR APATINIB AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE 2 TRIAL2022Diseases of the Esophagus论文
  43. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  44. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  45. Analysis of the crosstalk between EMT-related gene and Tumor-infiltrating immune cell in Esophageal Squamous Cell Carcinoma2022Research Square预印本
  46. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  47. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  48. Prediction of Postoperative Survival Level of Esophageal Cancer Patients Based on Kaplan-Meier (K-M) Survival Analysis and Gray Wolf Optimization (GsWO)-BP Model2022Communications in computer and information science会议论文
  49. Preliminary study on the role and mechanism of KIRREL3 in the development of esophageal squamous cell carcinoma (ESCC)2022Research Square预印本
  50. Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.2022Journal of Clinical Oncology会议摘要
  51. 151 A RANDOMIZED,OPEN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF ANLOTINIB PLUS IRINOTECAN VERSUS IRINOTECAN IN PATIENTS WITH ESCC2021Diseases of the Esophagus论文
  52. 155 A META-ANALYSIS OF EFFICACY AND SAFETY OF ANTI-BODIES TARGETING PD-1 IN TREATMENT OF ADVANCED ESOPHAGEAL CANCER2021Diseases of the Esophagus综述
  53. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncology论文
  54. 159 METFORMIN DOWNREGULATES PD-L1 EXPRESSION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY INHIBITING IL-6 SIGNALING PATHWAY2021Diseases of the Esophagus论文
  55. 659 AN SINGLE-ARM OPEN-LABEL PHASE II STUDY OF CAMRELIZUMAB PLUS APATINIB AS SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagus论文
  56. 740 CAMRELIZUMAB IN COMBINATION WITH PREOPERATIVE CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY2021Diseases of the Esophagus论文
  57. Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncology会议摘要
  58. Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncology会议摘要
  59. Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.2021Journal of Clinical Oncology会议摘要
  60. Correction to: Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression2021Journal of Experimental & Clinical Cancer Research勘误
  61. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  62. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  63. Identify risk factors and predict the postoperative risk of ESCC using ensemble learning2021Biomedical Signal Processing and Control论文
  64. LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway2021Research Square预印本
  65. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  66. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  67. LncRNA NCK1-AS1 is overexpressed in esophageal squamous cell carcinoma and predicts survival2021Research Square预印本
  68. Preliminary Study on the Role and Mechanism of KIRREL3 in the Development of Esophageal Squamous Cell Carcinoma (ESCC)2021Research Square预印本
  69. Progress of Exosome in the Pathogenesis, Diagnosis and Treatment of Esophageal Squamous Cell Carcinoma2021Cancer Cell Research论文
  70. The Efficacy and Safety of Anti-bodies Targeting PD-1 for Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-analysis2021Research Square预印本
  71. The anticancer effects of Levonorgestrel on human esophageal squamous carcinoma cells2021Research Square预印本
  72. [Retracted] HNF1A‑AS1 promotes growth and metastasis of esophageal squamous cell carcinoma by sponging miR‑214 to upregulate the expression of SOX-42021International Journal of Oncology论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 169 篇,占 1.1%。

牵头论文
169
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 323220212022: 464620222023: 353520232024: 333320242025: 19192025

郑州有 3 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
    分期
    IV期
    开始
    2024-12
    登记号
    NCT06930573

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  2. 即将招募
    A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
    分期
    IV期
    开始
    2026-08
    登记号
    NCT07790419

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  3. 正在招募
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-05
    登记号
    NCT06954467

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙

  4. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  5. 正在招募
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-11
    登记号
    NCT07209813

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南京、南昌、杭州、郑州、长沙

  6. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  7. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  8. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

  9. 正在招募
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2022-02
    登记号
    NCT05155189

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 1 家列出的医院为研究中心杭州、郑州

  10. 正在招募
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    分期
    I/II期
    开始
    2021-11
    登记号
    NCT05024214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、广州、杭州、沈阳、珠海、福州、蚌埠、郑州、长春

  11. 即将招募
    A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
    分期
    未注明
    开始
    2025-03
    登记号
    NCT06823050

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

  12. 即将招募
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07100236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州

  13. 即将招募
    A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
    分期
    未注明
    开始
    2025-10
    登记号
    NCT07156617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心南昌、海口、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科病理/检验科
牵头的论文169
  1. EMC3 as a Novel Biomarker and Driver of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Progression.2026Annals of surgical oncology
  2. Exosomal FOSL1 From Cancer-associated Fibroblasts Drives the Progression and Pro-tumorigenic M2 Macrophage Polarization of Hepatocellular Carcinoma By Activating PLAU Transcription.2026Applied biochemistry and biotechnology
  3. TMX1 promotes the progression of hepatocellular carcinoma by inhibiting ferroptosis via stabilizing FABP5.2026Cellular signalling
  4. Targeted delivery of IFN-α-anti-GPC3 fusion protein via mRNA-LNP platform elicits potent anti-tumor immunity in hepatocellular carcinoma.2026Drug delivery and translational research
  5. PLAUR+ Neutrophils Drive Anti-PD-1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  6. m6A methylation-mediated lncRNA RNF144A-AS1 promotes hepatocellular carcinoma progression through the miR-1301-3p/RNF38 pathway.2025Biology direct免费全文
  7. L-741626 inhibits hepatocellular carcinoma progression by targeting Ref-1 to suppress MAPK/ERK signalling pathway activity.2025Biology direct免费全文
  8. HOXB4/METTL7B cascade mediates malignant phenotypes of hepatocellular carcinoma through TKT m6A modification.2025Biology direct免费全文
  9. Thermal ablation for pulmonary oligometastases from hepatocellular carcinoma: initial experience and retrospective study.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  10. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  11. Targeting YBX1-m5C mediates RNF115 mRNA circularisation and translation to enhance vulnerability of ferroptosis in hepatocellular carcinoma.2025Clinical and translational medicine免费全文
  12. LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression.2025Current cancer drug targets
  13. Single-cell sequencing and machine learning reveal the role of dioxin-interacting genes in HCC prognosis and immune microenvironment.2025Ecotoxicology and environmental safety
  14. Current research of the Notch pathway in hepatocellular carcinoma.2025European journal of medical research免费全文
  15. An immune cell activation signature reflected hepatocellular carcinoma heterogeneity and predicted clinical outcomes.2025Frontiers in immunology免费全文
  16. Integrated multi-omics analysis and machine learning refine molecular subtypes and prognosis in hepatocellular carcinoma through O-linked glycosylation genes.2025Functional & integrative genomics
  17. HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma.2025Hepatology communications免费全文
  18. ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy.2025International journal of nanomedicine免费全文
  19. Genome-Scale CRISPR-Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC.2025Journal of gastroenterology and hepatology
  20. Programmed cell death-related genes define distinct molecular subtypes and risk profiles in hepatocellular carcinoma.2025Scientific reports免费全文
  21. The EZ-ALBI and PALBI scores contribute to the clinical application of ALBI in predicting postoperative recurrence of HCC.2025Scientific reports免费全文
  22. BRD4 interacting genes as prognostic biomarkers in hepatocellular carcinoma for optimized treatment strategies.2025Scientific reports免费全文
  23. Prediction of microvascular invasion in hepatocellular carcinoma using a preoperative serum C-reactive protein-based nomogram.2025Scientific reports免费全文
  24. In Situ Nanofiber Patch Boosts Postoperative Hepatocellular Carcinoma Immune Activation by Trimodal Combination Therapy.2024ACS nano免费全文
  25. Differentiation of confluent hepatic fibrosis and infiltrative hepatocellular carcinoma on MR imaging.2024Abdominal radiology (New York)
  26. High ratio of resident to exhausted CD4 + T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma.2024BMC cancer免费全文
  27. Comprehensive analysis of POLH-AS1 as a prognostic biomarker in hepatocellular carcinoma.2024BMC cancer免费全文
  28. Ferroptosis-related lncRNA NRAV affects the prognosis of hepatocellular carcinoma via the miR-375-3P/SLC7A11 axis.2024BMC cancer免费全文
  29. Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma.2024Biology direct免费全文
  30. Analytical and Diagnostic Performance of a Dual-Target Blood Detection Test for Hepatocellular Carcinoma.2024Cancer reports (Hoboken, N.J.)免费全文
  31. Arachidonic acid metabolism CYP450 pathway is deregulated in hepatocellular carcinoma and associated with microvascular invasion.2024Cell biology international
  32. NFKBIZ regulates NFκB signaling pathway to mediate tumorigenesis and metastasis of hepatocellular carcinoma by direct interaction with TRIM16.2024Cellular and molecular life sciences : CMLS免费全文
  33. The role of abnormal ubiquitination in hepatocellular carcinoma pathology.2024Cellular signalling
  34. USP24 promotes autophagy-dependent ferroptosis in hepatocellular carcinoma by reducing the K48-linked ubiquitination of Beclin1.2024Communications biology免费全文
  35. Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer.2024Drug delivery and translational research
  36. Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma.2024Epigenetics免费全文
  37. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.2024European radiologyRCT
  38. A Predictive Model Based on the FBXO Family Reveals the Significance of Cyclin F in Hepatocellular Carcinoma.2024Frontiers in bioscience (Landmark edition)
  39. Development of a prognostic scoring system for hepatic vena cava Budd-Chiari syndrome with hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  40. Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE.2024Hepatology communications免费全文
  41. Delivery of SiRNA-PD-L1 by attenuated Salmonella in combination with oxaliplatin in a hepatocellular carcinoma mouse model.2024International immunopharmacology
  42. SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma.2024International immunopharmacology
  43. MARCH5 promotes hepatocellular carcinoma progression by inducing p53 ubiquitination degradation.2024Journal of cancer research and clinical oncology免费全文
  44. Integrated Exploration of Epigenetic Dysregulation Reveals a Stemness/EMT Subtype and MMP12 Linked to the Progression and Prognosis in Hepatocellular Carcinoma.2024Journal of proteome research
  45. BTF3 affects hepatocellular carcinoma progression by transcriptionally upregulating PDCD2L and inactivating p53 signaling.2024Molecular medicine (Cambridge, Mass.)免费全文
  46. Targeted immune cell therapy for hepatocellular carcinoma using expanded liver mononuclear cell-derived natural killer cells.2024Neoplasia (New York, N.Y.)免费全文
  47. NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma.2024Oncogene
  48. DNA methylation and gene expression profiling reveal potential association of retinol metabolism related genes with hepatocellular carcinoma development.2024PeerJ免费全文
  49. Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein.2024PloS one免费全文
  50. Deficiency of betaine-homocysteine methyltransferase activates glucose-6-phosphate dehydrogenase (G6PD) by decreasing arginine methylation of G6PD in hepatocellular carcinogenesis.2024Science China. Life sciences
  51. Single-cell transcriptomics reveals over-activated reactive oxygen species pathway in hepatocytes in the development of hepatocellular carcinoma.2024Scientific reports免费全文
  52. Construction and validation of a prognostic signature based on microvascular invasion and immune-related genes in hepatocellular carcinoma.2024Scientific reports免费全文
  53. FKBP4 promotes glycolysis and hepatocellular carcinoma progression via p53/HK2 axis.2024Scientific reports免费全文
  54. Multi-omic analysis identifies the molecular mechanism of hepatocellular carcinoma with cirrhosis.2024Scientific reports免费全文
  55. Novel molecular hepatocellular carcinoma subtypes and RiskScore utilizing apoptosis-related genes.2024Scientific reports免费全文
  56. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicent2024Signal transduction and targeted therapyRCT免费全文
  57. Machine Learning-Based Development of Nomogram for Hepatocellular Carcinoma to Predict Acute Liver Function Deterioration After Drug-Eluting Beads Transarterial Chemoembolization.2023Academic radiologyRCT
  58. Classification of Signature-Based Phenotypes of Aging-Related Genes to Identify Prognostic and Immune Characteristics in HCC.2023Analytical cellular pathology (Amsterdam)免费全文
  59. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.2023BMC cancer免费全文
  60. Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma.2023BMC cancer免费全文
  61. TACE sequential MWA guided by cone-beam computed tomography in the treatment of small hepatocellular carcinoma under the hepatic dome.2023BMC cancer免费全文
  62. Comprehensive analysis of candidate signatures of long non-coding RNA LINC01116 and related protein-coding genes in patients with hepatocellular carcinoma.2023BMC gastroenterology免费全文
  63. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.2023Cancer biology & therapy免费全文
  64. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  65. Homologous cancer cell membrane-camouflaged nanoparticles target drug delivery and enhance the chemotherapy efficacy of hepatocellular carcinoma.2023Cancer letters
  66. AARS2 as a novel biomarker for prognosis and its molecular characterization in pan-cancer.2023Cancer medicine免费全文
  67. Oncogenic pathways refine a new perspective on the classification of hepatocellular carcinoma.2023Cellular signalling
  68. The prognosis and clinicopathological significance of histone deacetylase in hepatocellular carcinoma: a meta-analysis.2023Clinical and experimental medicine
  69. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.2023Clinical and experimental medicine
  70. Implications of pseudogenes for the prognosis of hepatocellular carcinoma.2023Clinical and translational medicine免费全文
  71. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.2023Clinics and research in hepatology and gastroenterology
  72. DTL is a Novel Downstream Gene of E2F1 that Promotes the Progression of Hepatocellular Carcinoma.2023Current cancer drug targets
  73. Letter to the editor regarding "PET imaging of hepatocellular carcinoma by targeting tumor‑associated endothelium using [68 Ga]Ga‑PSMA‑617".2023European journal of nuclear medicine and molecular imaging
  74. Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study.2023Frontiers in immunology免费全文
  75. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  76. Deubiquitinating enzyme Josephin-2 stabilizes PHGDH to promote a cancer stem cell phenotype in hepatocellular carcinoma.2023Genes & genomics
  77. NSUN2-mediated mRNA m5C Modification Regulates the Progression of Hepatocellular Carcinoma.2023Genomics, proteomics & bioinformatics免费全文
  78. The latest research progress on minimally invasive treatments for hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  79. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.2023Hepatology international免费全文
  80. TACC3 is an independent prognostic marker, and knockdown of TACC3 enhances the efficacy of CDK1 inhibitor RO3306 in liver cancer cells.2023Journal of biochemical and molecular toxicology
  81. Clinical Outcomes of Drug-eluting Beads Transarterial Chemoembolization for Unresectable Gastric Carcinoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  82. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues.2023Journal of translational medicine免费全文
  83. m6 A reader YTHDF3 triggers the progression of hepatocellular carcinoma through the YTHDF3/m6 A-EGFR/STAT3 axis and EMT.2023Molecular carcinogenesis
  84. LATS-regulated nuclear-cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial-mesenchymal transition.2023Molecular carcinogenesis
  85. SUMOylation of RNF146 results in Axin degradation and activation of Wnt/β-catenin signaling to promote the progression of hepatocellular carcinoma.2023Oncogene
  86. Comment on: Alnustone inhibits the growth of hepatocellular carcinoma via reactive oxygen species-mediated PI3K/Akt/mTOR/p70S6K axis.2023Phytotherapy research : PTR
  87. Identification and validation of candidate clinical signatures of apolipoprotein L isoforms in hepatocellular carcinoma.2023Scientific reports免费全文
  88. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.2023Scientific reports免费全文
  89. NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma.2023Scientific reports免费全文
  90. Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma.2023The international journal of biochemistry & cell biology
  91. Circ_0073228 serves as a competitive endogenous ribonucleic acid to facilitate proliferation and inhibit apoptosis of hepatocellular carcinoma cells by the miR-139-5p/deoxyribonuclease II axis.2023The journal of gene medicine
  92. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.2022BMC cancer免费全文
  93. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.2022BMC cancer免费全文
  94. GSG2 promotes tumor growth through regulating cell proliferation in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  95. Circular RNA circ_0001955 promotes hepatocellular carcinoma tumorigenesis by up-regulating alkaline ceramidase 3 expression through microRNA-655-3p.2022Bioengineered免费全文
  96. The role of NCAPG in various of tumors.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  97. LINC00958: A promising long non-coding RNA related to cancer.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  98. A hypoxia-related prognostic model predicts overall survival and treatment response in hepatocellular carcinoma.2022Bioscience reports免费全文
  99. Single-cell transcriptomics analysis reveals intratumoral heterogeneity and identifies a gene signature associated with prognosis of hepatocellular carcinoma.2022Bioscience reports免费全文
  100. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.2022Canadian journal of gastroenterology & hepatology免费全文
  101. CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex.2022Cancer gene therapy
  102. Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities.2022Cancer letters
  103. Fluid shear stress induces cell migration via RhoA-YAP1-autophagy pathway in liver cancer stem cells.2022Cell adhesion & migration免费全文
  104. Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC.2022Cell death & disease免费全文
  105. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.2022Clinics and research in hepatology and gastroenterology
  106. Congenital intrahepatic portosystemic shunt with invasive hepatocellular carcinoma.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  107. Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma.2022Disease markers免费全文
  108. Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway.2022Drug design, development and therapy免费全文
  109. Long Noncoding RNAs Hepatocyte Nuclear Factor 4A Antisense RNA 1 and Hepatocyte Nuclear Factor 1A Antisense RNA 1 Are Involved in Ritonavir-Induced Cytotoxicity in Hepatoma Cells.2022Drug metabolism and disposition: the biological fate of chemicals免费全文
  110. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.2022Frontiers in endocrinology免费全文
  111. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  112. Analysis on heterogeneity of hepatocellular carcinoma immune cells and a molecular risk model by integration of scRNA-seq and bulk RNA-seq.2022Frontiers in immunology免费全文
  113. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.2022Frontiers in immunology免费全文
  114. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.2022Frontiers in immunology免费全文
  115. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma.2022Frontiers in immunology免费全文
  116. Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  117. A Novel m1A-Score Model Correlated With the Immune Microenvironment Predicts Prognosis in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  118. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  119. Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma.2022International immunopharmacology
  120. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma.2022International immunopharmacology
  121. 3.0-T closed MR-guided microwave ablation for HCC located under the hepatic dome: a single-center experience.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  122. Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value.2022Journal of cancer research and clinical oncology免费全文
  123. Endoplasmic Reticulum Stress-Related Signature for Predicting Prognosis and Immune Features in Hepatocellular Carcinoma.2022Journal of immunology research免费全文
  124. Study on the Prognostic Values of TTC36 Correlated with Immune Infiltrates and Its Methylation in Hepatocellular Carcinoma.2022Journal of immunology research免费全文
  125. Combined Chemoembolization with Iodine-125 Seed Implantation for the Treatment of an Oromaxillary Carcinoma: A Case Report.2022Journal of vascular and interventional radiology : JVIR
  126. Drug-Eluting Embolics Chemoembolization for the Management of Recurrent or Advanced Head and Neck Cancer.2022Journal of vascular and interventional radiology : JVIR
  127. LncCDCA3L inhibits cell proliferation via a novel RNA structure-based crosstalk with CDCA3 in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  128. SPC25 promotes hepatocellular carcinoma metastasis via activating the FAK/PI3K/AKT signaling pathway through ITGB4.2022Oncology reports免费全文
  129. A novel classification of HCC basing on fatty-acid-associated lncRNA.2022Scientific reports免费全文
  130. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity.2022Scientific reports免费全文
  131. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma.2022Scientific reports免费全文
  132. Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders.2022Scientific reports免费全文
  133. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.2022Scientific reports免费全文
  134. Clinical observation of transcatheter arterial chemoembolization in super-aged patients with advanced gastric cancer.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  135. PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway.2022Toxicology and applied pharmacology
  136. RING finger and WD repeat domain 3 regulates proliferation and metastasis through the Wnt/β-catenin signalling pathways in hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  137. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.2022World journal of surgical oncology免费全文
  138. Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer.2021Abdominal radiology (New York)
  139. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer.2021Abdominal radiology (New York)
  140. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures.2021Academic radiology
  141. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1.2021Aging免费全文
  142. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.2021Aging免费全文
  143. Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer af2021Annals of palliative medicine
  144. Comment on Regarding Manuscript "Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systemic Review and Meta-analysis".2021Annals of surgery
  145. MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia?2021BMC cancer免费全文
  146. Image-guided microwave ablation of hepatocellular carcinoma (≤5.0 cm): is MR guidance more effective than CT guidance?2021BMC cancer免费全文
  147. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.2021BMC gastroenterology免费全文
  148. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network.2021Bioscience reports免费全文
  149. Down-regulation of RBP4 indicates a poor prognosis and correlates with immune cell infiltration in hepatocellular carcinoma.2021Bioscience reports免费全文
  150. Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma.2021Canadian journal of gastroenterology & hepatology免费全文
  151. Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma-A Propensity Analysis.2021Cardiovascular and interventional radiology
  152. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  153. Ultrasound-guided percutaneous metal-organic frameworks based codelivery system of doxorubicin/acetazolamide for hepatocellular carcinoma therapy.2021Clinical and translational medicine免费全文
  154. Predicting postoperative liver cancer death outcomes with machine learning.2021Current medical research and opinion
  155. LncRNA miR503HG inhibits epithelial-mesenchymal transition and angiogenesis in hepatocellular carcinoma by enhancing PDCD4 via regulation of miR-15b.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  156. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma.2021Future oncology (London, England)
  157. hMex-3A is associated with poor prognosis and contributes to the progression of hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  158. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.2021International immunopharmacology
  159. Enhancement of interferon gamma stability as an anticancer therapeutic protein against hepatocellular carcinoma upon interaction with calycosin.2021International journal of biological macromolecules
  160. Making timely remedial measures after TACE based on the results of cone-beam CT liver perfusion.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  161. High expression of DHX9 promotes the growth and metastasis of hepatocellular carcinoma.2021Journal of clinical laboratory analysis免费全文
  162. Screening Prognosis-Related lncRNAs Based on WGCNA to Establish a New Risk Score for Predicting Prognosis in Patients with Hepatocellular Carcinoma.2021Journal of immunology research免费全文
  163. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.2021Journal of translational medicine免费全文
  164. MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases.2021Laboratory medicine
  165. Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1.2021Pharmacological research
  166. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.2021PloS one免费全文
  167. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.2021Scientific reports免费全文
  168. CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis.2021Scientific reports免费全文
  169. Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls.2021The Journal of steroid biochemistry and molecular biology
中文论文(未计入)4
  1. [Effect and mechanism of tigecycline on proliferation of liver tumor cells in mouse model].2025Zhonghua yi xue za zhi
  2. [Efficacy analysis of hepatic arterial infusion chemotherapy combined with targeted and immune therapy followed by 125I seeds implantation in the treatment of hepatocellular carcinoma with portal vain tumor thrombus].2024Zhonghua yi xue za zhi
  3. [Analysis of curative effects of chemoembolization with drug-loaded microspheres of different particle sizes for the treatment of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Safety and efficacy of cryoablation versus radiofrequency ablation for stage Ⅰ non-small-cell lung cancer].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
  1. A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk正在招募NCT06930573牵头方IV期2024-12 启动
  2. Novel Treatment of Advanced Hepatocellular Carcinoma状态不明NCT03950518牵头方III期2019-04 启动
  3. Treatment of Intermediate-stage Hepatocellular Carcinoma状态不明NCT03274427牵头方III期2017-07 启动
  4. Treatment of Advanced Hepatocellular Carcinoma状态不明NCT03278444牵头方III期2017-07 启动
  5. A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion即将招募NCT07790419牵头方(推断)IV期2026-08 启动
  6. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07209813研究中心II期2025-11 启动
  7. A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data即将招募NCT07156617研究中心2025-10 启动
  8. A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC即将招募NCT06823050研究中心2025-03 启动
  9. 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness即将招募NCT07100236研究中心2025-08 启动
  10. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma正在招募NCT06954467研究中心II期2025-05 启动
  11. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  12. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  13. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  14. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  15. A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma正在招募NCT05155189研究中心I期2022-02 启动
  16. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors正在招募NCT05024214研究中心I/II期2021-11 启动
  17. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  18. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients状态不明NCT05343832研究中心2021-11 启动
  19. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  20. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  21. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  22. Chimeric Antigen Receptor T Cells Targeting Glypican-3已完成NCT03884751研究中心I期2019-08 启动
  23. Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies状态不明NCT03638206研究中心I/II期2018-03 启动
  24. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 105 篇,占 1.1%。

牵头论文
105
2021–2025 年
牵头试验
10
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
12
由其他机构牵头
每年牵头的论文数
2021: 191920212022: 131320222023: 262620232024: 252520242025: 18182025

郑州有 4 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
    分期
    II期
    开始
    2025-06
    登记号
    NCT07294664

    年龄 18 岁 至 未注明(登记的条件)

    牵头:郑州大学第一附属医院郑州

  2. 正在招募
    A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
    分期
    II期
    开始
    2025-06
    登记号
    NCT07770113

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院;另有 1 家列出的医院为研究中心洛阳、郑州

  3. 正在招募
    Energy CT in Imaging and Diagnosis of Gastric Cancer
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06869694

    年龄 18 岁 至 未注明(登记的条件)

    牵头:郑州大学第一附属医院郑州

  4. 即将招募
    IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
    分期
    I/II期
    开始
    2026-03
    登记号
    NCT07361991

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  5. 即将招募
    RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
    分期
    II期
    开始
    2024-07
    登记号
    NCT06492317

    年龄 18 岁 至 未注明(登记的条件)

    牵头:郑州大学第一附属医院郑州

  6. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  7. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  8. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  9. 正在招募
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
    分期
    II期
    开始
    2025-09
    登记号
    NCT07102901

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、郑州

  10. 正在招募
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    分期
    II期
    开始
    2025-12
    登记号
    NCT07127822

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛

  11. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  12. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  13. 正在招募
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    分期
    II期
    开始
    2024-10
    登记号
    NCT06730373

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院;另有 7 家列出的医院为研究中心临沂、济南、淄博、烟台、郑州、青岛

  14. 正在招募
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    分期
    未注明
    开始
    2023-01
    登记号
    NCT05722275

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州

  15. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  16. 正在招募
    a Single-arm, Single-center, Open Clinical Study
    分期
    未注明
    开始
    2023-07
    登记号
    NCT06431100

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

  17. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术腹膜转移与晚期
论文中的科室消化/肝病科影像/核医学科肿瘤内科普外/肝胆胰外科
牵头的论文105
  1. Photo-triggered engineered microbes achieving dual epigenetic immunomodulation for gastric cancer.2026Biomaterials
  2. Interpretable machine learning model using dual-energy CT for predicting adverse histopathological status in gastric cancer: A multicenter study.2026European journal of radiology
  3. Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study.2026European radiology
  4. m6A-Modified BASP1 Regulates IL6 Expression to Induce TAM Infiltration to Promote Gastric Cancer Progression.2026Journal of gastroenterology and hepatology
  5. CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.2025Academic radiology
  6. WSGC@FA@PEG/PEI-SPIONs Mitigate Chemoresistance in Gastric Adenocarcinoma by Modulating the Notch Signaling Pathway and Mitophagy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  7. Long transparent cap-assisted clip closure technique: a new choice for gastrointestinal defect closure.2025BMC gastroenterology免费全文
  8. Construction and validation of a novel nomogram based on the log odds of positive lymph nodes to predict cancer-specific survival in elderly patients with gastric adenocarcinoma after radical surgery.2025BMC gastroenterology免费全文
  9. Development of a nomogram for the prediction of postoperative survival in hepatoid adenocarcinoma of the stomach.2025Carcinogenesis
  10. Chidamide enhances the sensitivity of gastric cancer to 5-fluorouracil chemotherapy by suppressing the HDAC3/HNF4A/TYMS axis.2025Cell death & disease免费全文
  11. PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive angiogenesis of gastric cancer.2025Cellular signalling
  12. Longitudinal changes in tumor morphology and body composition following neoadjuvant chemotherapy predict progression-free survival in adenocarcinoma of the esophagogastric junction: A multi-center study.2025European journal of radiology
  13. Radiomics analysis of dual-energy CT-derived iodine maps for differentiating between T1/2 and T3/4a in gastric cancer: A multicenter study.2025European journal of radiology
  14. Dual-energy CT for predicting progression-free survival of locally advanced gastric cancer after gastrectomy: Insights into tumor angiogenesis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  15. Pygo2+ T cells possess immunosuppressive features and inferior immunotherapeutic response in gastric cancer.2025Frontiers in immunology免费全文
  16. Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors.2025Frontiers in immunology免费全文
  17. Clinical and pathological characteristics and treatment of gastric cancer during pregnancy.2025Indian journal of cancer
  18. Transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization for advanced gastric fundus and cardia cancer with obstruction.2025Journal of cancer research and clinical oncology免费全文
  19. [Expression of Concern] Combination of the FGFR4 inhibitor PD173074 and 5‑fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.2025Oncology reports免费全文
  20. Ailanthone targets mitophagy-loaded SIRT4 to facilitate the deacetylation of HIF1α, triggering oxidative stress for gastric carcinoma treatment.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  21. A signature based on efferocytosis-related genes for the evaluation of prognosis and the tumour microenvironment in gastric cancer.2025Scientific reports免费全文
  22. Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy.2025World journal of gastroenterology免费全文
  23. The short peptide encoded by long non-coding RNA RNF217-AS1 inhibits stomach cancer tumorigenesis, macrophage recruitment, and pro-inflammatory responses.2024Amino acids免费全文
  24. Gastric-type adenocarcinoma of the uterine cervix: A case report.2024Asian journal of surgery
  25. A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study.2024BMC cancer免费全文
  26. Pomiferin targeting SLC9A9 based on histone acetylation modification pattern is a potential therapeutical option for gastric cancer with high malignancy.2024Biochemical pharmacology
  27. Novel metabolic biomarker for early detection and diagnosis to the patients with gastric cardia adenocarcinoma.2024Cancer medicine免费全文
  28. miR-1304 targets KLK11 to regulate gastric cancer cell proliferation through the mTOR signaling pathway.2024Carcinogenesis
  29. POU6F1 promotes ferroptosis by increasing lncRNA-CASC2 transcription to regulate SOCS2/SLC7A11 signaling in gastric cancer.2024Cell biology and toxicology免费全文
  30. TGF-β-driven LIF expression influences neutrophil extracellular traps (NETs) and contributes to peritoneal metastasis in gastric cancer.2024Cell death & disease免费全文
  31. Endoscopic resection of extra-luminal gastric gastrointestinal stromal tumors using a snare assisted external traction technique (with video).2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  32. Gastric adenocarcinoma of fundic gland type.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  33. Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors.2024Digestive diseases and sciences
  34. Easy and Feasible Closure for a Large Perforation After Gastric Full-Thickness Resection: Clipping Method with Symmetrical Anchors.2024Digestive diseases and sciences
  35. Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer.2024Drug delivery and translational research
  36. Downregulation of short-stature homeobox protein 2 suppresses gastric cancer cell growth and stemness in vitro and in vivo via inactivating wnt/β-catenin signaling.2024Drug development research
  37. Downregulation of HIGD1B induces mitochondria-mediated apoptosis in gastric cancer cells by inactivating Akt and ERK pathways.2024Drug development research
  38. Multiple snares-assisted endoscopic full-thickness resection of a giant submucosal tumor at the esophagogastric junction.2024Endoscopy免费全文
  39. A dual-gene panel of two fragments of methylated IRF4 and one of ZEB2 in plasma cell-free DNA for gastric cancer detection.2024Epigenetics免费全文
  40. Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancer.2024European journal of medicinal chemistry
  41. Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.2024Frontiers in immunology免费全文
  42. Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.2024Frontiers in immunology免费全文
  43. CD19+CD73+ B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer.2024International immunopharmacology
  44. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer.2024International journal of biological macromolecules
  45. Preoperative prediction of microvascular/nerve invasion in locally advanced gastric cancer by differentiation and enhanced CT features.2024Medicine免费全文
  46. The expression and clinical significance of serine hydroxymethyltransferase2 in gastric cancer.2024PeerJ免费全文
  47. Evaluating nomogram models for predicting survival outcomes in gastric gastrointestinal stromal tumors with SEER database analysis.2024Scientific reports免费全文
  48. Analysis of influencing factors of nerve invasion in locally advanced gastric cancer.2023Abdominal radiology (New York)
  49. A rare case of gastric schwannoma resection complicating by multiorgan high-frequency electrical burns.2023Asian journal of surgery
  50. Tumor lost in the oral cavity during the removal process: A rare complication of endoscopic submucosal excavation.2023Asian journal of surgery
  51. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.2023BMC gastroenterology免费全文
  52. Predicting postoperative gastric cancer prognosis based on inflammatory factors and machine learning technology.2023BMC medical informatics and decision making免费全文
  53. Establishment and validation of a prognostic nomogram for postoperative patients with gastric cardia adenocarcinoma: A study based on the Surveillance, Epidemiology, and End Results database and a Chinese cohort.2023Cancer medicineRCT
  54. microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells.2023Cell biology and toxicology
  55. Macrophage-derived exosomes regulate gastric cancer cell oxaliplatin resistance by wrapping circ 0008253.2023Cell cycle (Georgetown, Tex.)免费全文
  56. Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer.2023Clinical epigenetics免费全文
  57. Identifying mitophagy-related genes as prognostic biomarkers and therapeutic targets of gastric carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data.2023Computers in biology and medicine
  58. Endoscopic full-thickness resection preserving the mucosa: more is better.2023Endoscopy免费全文
  59. Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: The combination of clinical and quantitative CT-imaging features.2023European journal of radiology
  60. Efficacy analysis of endoscopic treatment of giant gastric gastrointestinal stromal tumors (≥5 cm).2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  61. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.2023Frontiers in immunology免费全文
  62. Comprehensive analysis of immune-related lncRNAs and their clinical relevance in gastric adenocarcinoma.2023Functional & integrative genomics
  63. Is it time for the adoption of same-day discharge after endoscopic submucosal dissection?2023Gastrointestinal endoscopy
  64. The PSCA rs2294008 (C/T) Polymorphism Increases the Risk of Gastric and Bladder Cancer: A Meta-Analysis.2023Genetic testing and molecular biomarkers
  65. Predictive value of platelet-to-lymphocyte ratio combined with CA199 levels in postoperative survival of patients with gastric cancer: A retrospective study.2023International immunopharmacology
  66. Survival influence of gender on 42,345 patients with gastric cardia adenocarcinoma.2023Journal of cancer research and clinical oncology免费全文
  67. Prognostic value of blood lipids on patients treated with oxaliplatin combined with S-1 (SOX) after radical gastrectomy and establishment of prognostic nomogram.2023Journal of cancer research and clinical oncology免费全文
  68. FYN/TOPK/HSPB1 axis facilitates the proliferation and metastasis of gastric cancer.2023Journal of experimental & clinical cancer research : CR免费全文
  69. Short-term efficacy of additional laparoscopic-assisted radical gastrectomy after non-curative endoscopic submucosal dissection for early gastric cancer.2023Langenbeck's archives of surgery
  70. Effects of proximal gastrectomy with narrow gastric tube anastomosis compared with total gastrectomy with Roux-en-Y anastomosis on upper gastric cancer.2023Langenbeck's archives of surgery
  71. Bioinformatics analysis and experimental validation of tumorigenic role of PPIA in gastric cancer.2023Scientific reports免费全文
  72. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.2023Scientific reports免费全文
  73. Can visceral fat parameters based on computed tomography be used to predict occult peritoneal metastasis in gastric cancer?2023World journal of gastroenterology免费全文
  74. Abnormal phenotype of Nrf2 is associated with poor prognosis through hypoxic/VEGF-A-Rap1b/VEGFR2 pathway in gastric cancer.2022Aging免费全文
  75. Computed tomography features and clinicopathological characteristics of gastric glomus tumor.2022BMC gastroenterology免费全文
  76. From DNMT1 degrader to ferroptosis promoter: Drug repositioning of 6-Thioguanine as a ferroptosis inducer in gastric cancer.2022Biochemical and biophysical research communications
  77. MIR4435-2HG: A newly proposed lncRNA in human cancer.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  78. EGR1-CCL2 Feedback Loop Maintains Epithelial-Mesenchymal Transition of Cisplatin-Resistant Gastric Cancer Cells and Promotes Tumor Angiogenesis.2022Digestive diseases and sciences
  79. Testing lncRNAs signature as clinical stage-related prognostic markers in gastric cancer progression using TCGA database.2022Experimental biology and medicine (Maywood, N.J.)免费全文
  80. A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma.2022Frontiers in immunology免费全文
  81. Long non-coding RNA NEAT1 mediated RPRD1B stability facilitates fatty acid metabolism and lymph node metastasis via c-Jun/c-Fos/SREBP1 axis in gastric cancer.2022Journal of experimental & clinical cancer research : CR免费全文
  82. Comparison of short-term surgical outcomes between complete mesenteric resection and traditional transhiatal laparoscopic surgery for Siewert type II/III esophagogastric junction adenocarcinoma.2022Langenbeck's archives of surgery
  83. Stratified analysis of multiple management of gastric cancer: A population-based study of incidence, mortality and DALY.2022Medicine免费全文
  84. Clinical observation of transcatheter arterial chemoembolization in super-aged patients with advanced gastric cancer.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  85. Suppression of JNK/ERK dependent autophagy enhances Jaspine B derivative-induced gastric cancer cell death via attenuation of p62/Keap1/Nrf2 pathways.2022Toxicology and applied pharmacology
  86. Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients.2022World journal of surgical oncology免费全文
  87. TCGA-TCIA-Based CT Radiomics Study for Noninvasively Predicting Epstein-Barr Virus Status in Gastric Cancer.2021AJR. American journal of roentgenology
  88. Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer.2021AJR. American journal of roentgenology
  89. Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer.2021Aging免费全文
  90. Praja2 suppresses the growth of gastric cancer by ubiquitylation of KSR1 and inhibiting MEK-ERK signal pathways.2021Aging免费全文
  91. The inhibitory effect of human DEFA5 in growth of gastric cancer by targeting BMI1.2021Cancer science免费全文
  92. Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment.2021European journal of medicinal chemistry
  93. Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.2021European journal of medicinal chemistry
  94. Radiomics analysis of CT imaging for differentiating gastric neuroendocrine carcinomas from gastric adenocarcinomas.2021European journal of radiology
  95. Elevated linc00936 or silenced microRNA-425-3p inhibits immune escape of gastric cancer cells via elevation of ZC3H12A.2021International immunopharmacology
  96. Inhibiting the JNK/ERK signaling pathway with geraniol for attenuating the proliferation of human gastric adenocarcinoma AGS cells.2021Journal of biochemical and molecular toxicology
  97. Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression.2021Journal of cellular and molecular medicine免费全文
  98. miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway.2021Journal of clinical laboratory analysis免费全文
  99. Bcl-2-associated transcription factor 1 Ser290 phosphorylation mediates DNA damage response and regulates radiosensitivity in gastric cancer.2021Journal of translational medicine免费全文
  100. CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia‑induced damage.2021Molecular medicine reports免费全文
  101. Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma.2021Nature communications免费全文
  102. Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration.2021Oncology reports免费全文
  103. Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.2021Phytotherapy research : PTR免费全文
  104. A machine learning-based predictor for the identification of the recurrence of patients with gastric cancer after operation.2021Scientific reports免费全文
  105. Machine learning predicts lymph node metastasis of poorly differentiated-type intramucosal gastric cancer.2021Scientific reports免费全文
中文论文(未计入)4
  1. [The clinical characteristics of metastatic tumors in small intestine].2024Zhonghua yi xue za zhi
  2. [Influence of Psychological Factors on the Quality of Life of Patients with Non-surgical Gastric Cancer].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Diagnostic efficacy of a combined diagnostic model based on extreme gradient boosting algorithm in differentiating the pathological grading of gastric neuroendocrine neoplasms].2021Zhonghua yi xue za zhi
  4. [Expression of hepatocyte nuclear factor 4γ in gastric carcinoma and its role in cell proliferation and stemness].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)45
  1. IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer即将招募NCT07361991牵头方I/II期2026-03 启动
  2. PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer正在招募NCT07294664牵头方II期2025-06 启动
  3. A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer正在招募NCT07770113牵头方II期2025-06 启动
  4. RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer即将招募NCT06492317牵头方II期2024-07 启动
  5. Energy CT in Imaging and Diagnosis of Gastric Cancer正在招募NCT06869694牵头方2024-09 启动
  6. Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage状态不明NCT06194981牵头方2024-01 启动
  7. A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer状态不明NCT05241899牵头方II期2022-05 启动
  8. Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma状态不明NCT05024812牵头方I/II期2022-06 启动
  9. Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC状态不明NCT04819971牵头方II期2021-12 启动
  10. A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression进行中,不再招募NCT06939452牵头方(推断)II期2023-06 启动
  11. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  12. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  13. Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma正在招募NCT07102901研究中心II期2025-09 启动
  14. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer正在招募NCT07127822研究中心II期2025-12 启动
  15. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  16. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  17. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  18. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)正在招募NCT06730373研究中心II期2024-10 启动
  19. a Single-arm, Single-center, Open Clinical Study正在招募NCT06431100研究中心2023-07 启动
  20. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  21. Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics正在招募NCT05722275研究中心2023-01 启动
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  23. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  24. Clinical Study of Pan-cancer DNA Methylation Test in Plasma状态不明NCT05685524研究中心2022-07 启动
  25. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  26. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  27. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  28. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  29. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  30. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.已终止NCT05188209研究中心II期2021-12 启动
  31. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  32. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  33. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma已完成NCT05327231研究中心I期2020-07 启动
  34. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  35. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  36. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  37. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  38. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  39. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer已完成NCT04053205研究中心I/II期2019-11 启动
  40. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  41. Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies状态不明NCT03638206研究中心I/II期2018-03 启动
  42. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  43. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  44. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  45. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

郑州有 2 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科儿科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.7%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 2220242025: 002025

郑州有 6 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科放疗科

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Polydopamine-Based Targeted Nanosystem for Chemo/Photothermal Therapy of Retinoblastoma in a Mouse Orthotopic Model.2024International journal of nanomedicine
  2. Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis.2024The oncologist
  3. PRMT5 promotes retinoblastoma development.2023Human cell
  4. Long non-coding RNA XIST promotes retinoblastoma cell proliferation, migration, and invasion by modulating microRNA-191-5p/brain derived neurotrophic factor.2021Bioengineered
  5. microRNA-362-3p targets USP22 to retard retinoblastoma growth via reducing deubiquitination of LSD1.2021Cell cycle (Georgetown, Tex.)
早期论文(2016–2020 年)9
  1. Long noncoding RNA LINC00324 promotes retinoblastoma progression by acting as a competing endogenous RNA for microRNA-769-5p, thereby increasing STAT3 expression.2020Aging
  2. Carboplatin Inhibits the Progression of Retinoblastoma Through IncRNA XIST/miR-200a-3p/NRP1 Axis.2020Drug design, development and therapy
  3. Neferine induces mitochondrial dysfunction to exert anti-proliferative and anti-invasive activities on retinoblastoma.2020Experimental biology and medicine (Maywood, N.J.)
  4. Circular RNA (circ-0075804) promotes the proliferation of retinoblastoma via combining heterogeneous nuclear ribonucleoprotein K (HNRNPK) to improve the stability of E2F transcription factor 3 E2F3.2020Journal of cellular biochemistry
  5. SKP2, positively regulated by circ_ODC1/miR-422a axis, promotes the proliferation of retinoblastoma.2020Journal of cellular biochemistry
  6. MiR-25-3p promotes malignant phenotypes of retinoblastoma by regulating PTEN/Akt pathway.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. miR‑34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE‑A/p53 signaling.2019International journal of oncology
  8. LncRNA HOTAIR/miR-613/c-met axis modulated epithelial-mesenchymal transition of retinoblastoma cells.2018Journal of cellular and molecular medicine
  9. miR106b regulates retinoblastoma Y79 cells through Runx3.2017Oncology reports

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 4 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
中文论文(未计入)1
  1. [Surgical techniques for the safe and rapid resection of primary or secondary sacral tumors located between the second and fourth sacral vertebrae].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
早期论文(2016–2020 年)2
  1. A unique case of eyelid metastasis from chondroid chordoma.2019Indian journal of pathology & microbiology
  2. Differentiating skull base chordomas and invasive pituitary adenomas with conventional MRI.2018Acta radiologica (Stockholm, Sweden : 1987)

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 33 篇,占 1.5%。

牵头论文
33
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 6620222023: 8820232024: 5520242025: 442025

郑州有 16 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科儿科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文33
  1. Mapping Knowledge Structure and Themes Trends of Ewing Sarcoma: A Text-Mining Study.2025Annals of surgical oncology
  2. NSUN2 promotes osteosarcoma metastasis via stabilizing UBE2S mRNA in an m5C-dependent manner.2025Cellular signalling
  3. Enhancing doxorubicin sensitivity in osteosarcoma via iRGD-modified biomimetic nanoparticles targeting MCAM m6A modification.2025Journal of translational medicine
  4. Menin inhibitor MI-503 exhibits potent anti-cancer activity in osteosarcoma.2025Scientific reports
  5. Primary intraspinal capicua transcriptional repressor-rearranged sarcoma with adjacent vertebral bone destruction: The imaging diagnostic clues.2024Asian journal of surgery
  6. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.2024Biology direct
  7. Inhibition of discoidin domain receptor 1 as a new therapeutic strategy for osteosarcoma.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  8. SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression.2024JCI insight
  9. Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation.2024Journal of biochemical and molecular toxicology
  10. Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.2023Aging
  11. HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth.2023Cell death & disease
  12. WTAP contributes to the tumorigenesis of osteosarcoma via modulating ALB in an m6A-dependent manner.2023Environmental toxicology
  13. Propofol Regulates ER Stress to Inhibit Tumour Growth and Sensitize Osteosarcoma to Doxorubicin.2023International journal of clinical practice
  14. Circ_001422 aggravates osteosarcoma progression through targeting miR-497-5p/E2F3 axis.2023Journal of biochemical and molecular toxicology
  15. A novel CircRNA Circ_0001722 regulates proliferation and invasion of osteosarcoma cells through targeting miR-204-5p/RUNX2 axis.2023Journal of cancer research and clinical oncology
  16. A short peptide LINC00665_18aa encoded by lncRNA LINC00665 suppresses the proliferation and migration of osteosarcoma cells through the regulation of the CREB1/RPS6KA3 interaction.2023PloS one
  17. Studying the mechanism underlying lipid metabolism in osteosarcoma based on transcriptomic RNA sequencing and single-cell data.2023The journal of gene medicine
  18. Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma.2022Bioengineered
  19. TRPM2-AS promotes the malignancy of osteosarcoma cells by targeting miR-15b-5p/PPM1D axis.2022Cell cycle (Georgetown, Tex.)
  20. Hypoxia inducible factor-3α promotes osteosarcoma progression by activating KDM3A-mediated demethylation of SOX9.2022Chemico-biological interactions
  21. A novel prognostic signature in osteosarcoma characterised from the perspective of unfolded protein response.2022Clinical and translational medicine
  22. Cellular nanomechanics derived from pattern-dependent focal adhesion and cytoskeleton to balance gene transfection of malignant osteosarcoma.2022Journal of nanobiotechnology
  23. The prognostic factors of Ewing sarcoma/peripheral primitive neuroectodermal tumor: A retrospective analysis of 67 patients at a single center.2022Medicine
  24. Downregulation of long non-coding RNA UCA1 represses tumorigenesis and metastasis of osteosarcoma via miR-513b-5p/E2F5 axis.2021Anti-cancer drugs
  25. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.2021Cancer medicine
  26. Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients.2021Cancer medicine
  27. Knockdown of MCM8 functions as a strategy to inhibit the development and progression of osteosarcoma through regulating CTGF.2021Cell death & disease
  28. Hsa_circ_0032463 acts as the tumor promoter in osteosarcoma by regulating the miR‑330‑3p/PNN axis.2021International journal of molecular medicine
  29. Prognostic factors of chondroblastic osteosarcoma and nomogram development for prediction: A population-based, STROBE-compliant study.2021Medicine
  30. Clinical therapeutic effects of combined methotrexate and other chemotherapeutic agents in treating children and young patients with osteosarcoma: A protocol for systematic review and meta-analysis.2021Medicine
  31. Circular RNA hsa_circ_0032463 Acts as the Tumor Promoter in Osteosarcoma by Regulating the MicroRNA 498/LEF1 Axis.2021Molecular and cellular biology
  32. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.2021Pharmacological research
  33. Expression of immune-related genes as prognostic biomarkers for the assessment of osteosarcoma clinical outcomes.2021Scientific reports
早期论文(2016–2020 年)39
  1. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.2020Aging
  2. Upregulation of miRNA-154-5p prevents the tumorigenesis of osteosarcoma.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. Circular RNA_CNST Promotes the Tumorigenesis of Osteosarcoma Cells by Sponging miR-421.2020Cell transplantation
  4. Lung Metastasis Probability in Ewing Sarcoma: A Nomogram Based on the SEER Database.2020Current oncology (Toronto, Ont.)
  5. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.2020Journal of orthopaedic surgery and research
  6. [Clinical features and imaging analysis of primary bone lymphoma of the jaw].2020Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  7. Long non-coding RNA PVT1 encapsulated in bone marrow mesenchymal stem cell-derived exosomes promotes osteosarcoma growth and metastasis by stabilizing ERG and sponging miR-183-5p.2019Aging
  8. MIR210HG predicts poor prognosis and functions as an oncogenic lncRNA in hepatocellular carcinoma.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.2019Cancer medicine
  10. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis.2019Cell death & disease
  11. miR-671-5p Inhibits Tumor Proliferation by Blocking Cell Cycle in Osteosarcoma.2019DNA and cell biology
  12. Polyphyllin VI induces apoptosis and autophagy in human osteosarcoma cells by modulation of ROS/JNK activation.2019Drug design, development and therapy
  13. LncRNA ADPGK-AS1 regulated cell proliferation, invasion, migration and apoptosis via targeting miR-542-3p in osteosarcoma.2019European review for medical and pharmacological sciences
  14. Inhibitory effects of indirubin-3'-monoxime against human osteosarcoma.2019IUBMB life
  15. Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation.2019International journal of biological macromolecules
  16. lncRNA nuclear-enriched abundant transcript 1 promotes cell proliferation and invasion by targeting miR-186-5p/HIF-1α in osteosarcoma.2019Journal of cellular biochemistry
  17. miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.2019Journal of cellular biochemistry
  18. Inhibitory Effect of Sirtuin6 (SIRT6) on Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells.2019Medical science monitor : international medical journal of experimental and clinical research
  19. Evaluating and Predicting the Probability of Death in Patients with Non-Metastatic Osteosarcoma: A Population-Based Study.2019Medical science monitor : international medical journal of experimental and clinical research
  20. Prognosis of osteosarcomas in the mandible: 15-year experience of 55 patients.2019Medicine
  21. Identification of key genes in osteosarcoma by meta‑analysis of gene expression microarray.2019Molecular medicine reports
  22. miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/β-catenin signaling pathway.2019The international journal of biochemistry & cell biology
  23. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.2018Biochimica et biophysica acta. Molecular basis of disease
  24. Knockdown of long non-coding RNA TP73-AS1 inhibits osteosarcoma cell proliferation and invasion through sponging miR-142.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  25. miRNA-1284, a regulator of HMGB1, inhibits cell proliferation and migration in osteosarcoma.2018Bioscience reports
  26. SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway.2018Technology in cancer research & treatment
  27. RSF1 functions as an oncogene in osteosarcoma and is regulated by XIST/miR-193a-3p axis.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  28. Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells.2017Experimental cell research
  29. MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.2017Pathology, research and practice
  30. [Clinicopathologic analysis of Ewing-like BCOR-CCNB3 undifferentiated sarcoma].2017Zhonghua bing li xue za zhi = Chinese journal of pathology
  31. Fibulin-4 is a novel Wnt/β-Catenin pathway activator in human osteosarcoma.2016Biochemical and biophysical research communications
  32. Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.2016Biochemical and biophysical research communications
  33. MicroRNA-127-3p inhibits proliferation and invasion by targeting SETD8 in human osteosarcoma cells.2016Biochemical and biophysical research communications
  34. MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells.2016Oncology research
  35. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.2016Oncotarget
  36. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.2016Oncotarget
  37. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma.2016Oncotarget
  38. Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  39. Primary Ewing's Sarcoma/Primitive Neuroectodermal Tumor of Kidney with Caval Involvement in a Pregnant Woman.2016Urologia internationalis

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.5%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 5520242025: 112025

郑州有 5 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科影像/核医学科
牵头的论文8
  1. Endoscopic versus laparoscopic resection of gastrointestinal stromal tumors at the esophagogastric junction using propensity score matching analysis.2025Scientific reports
  2. Endoscopic resection of extra-luminal gastric gastrointestinal stromal tumors using a snare assisted external traction technique (with video).2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  3. Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors.2024Digestive diseases and sciences
  4. Appendiceal fecalith misdiagnosed as cecal stromal tumor: don't fall into the trap.2024Endoscopy
  5. Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST).2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Evaluating nomogram models for predicting survival outcomes in gastric gastrointestinal stromal tumors with SEER database analysis.2024Scientific reports免费全文
  7. Efficacy analysis of endoscopic treatment of giant gastric gastrointestinal stromal tumors (≥5 cm).2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  8. CTCF-activated SNHG16 facilitates gastrointestinal stromal tumor by targeting miR-128-3p/CASC3 axis.2022Experimental cell research
早期论文(2016–2020 年)6
  1. Diagnosis and Endoscopic Treatment of Gastrointestinal Stromal Tumors Arising from Esophagus.2020Journal of laparoendoscopic & advanced surgical techniques. Part A
  2. [Gastrointestinal glomus tumors: a clinicopathological analysis of fifteen cases].2020Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. Endoscopic gastroplasty as therapy for postoperative gastric distortion and stenosis.2019Endoscopy
  4. Gastric heterotopic pancreas and stromal tumors smaller than 3 cm in diameter: clinical and computed tomography findings.2018Cancer imaging : the official publication of the International Cancer Imaging Society
  5. Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report.2017BMC cancer
  6. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.2017Oncotarget
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 1.3%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 1120232024: 4420242025: 662025

郑州有 7 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科神经内科放疗科神经外科

这些论文过半是实验室或动物研究。

牵头的论文15
  1. Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy.2025BMC cancer
  2. The Pattern of Anemia in Pediatric Solid Tumors Prior to and after Chemotherapy- A Retrospective Cohort Study.2025Current cancer drug targets
  3. Comprehensive assessment of the significance of cellular senescence-associated genes in neuroblastoma.2025Genes & genomics
  4. Multiomics Analysis Reveals Neuroblastoma Molecular Signature Predicting Risk Stratification and Tumor Microenvironment Differences.2025Journal of proteome research
  5. Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities.2025Journal of proteome research
  6. A non-invasive diagnostic approach for neuroblastoma utilizing preoperative enhanced computed tomography and deep learning techniques.2025Scientific reports
  7. Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study.2024Cellular signalling
  8. Development of Neuroprotective Agents for the Treatment of Alzheimer's Disease using Conjugates of Serotonin with Sesquiterpene Lactones.2024Current medicinal chemistry
  9. Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma.2024Genes & genomics
  10. Corydaline alleviates Parkinson's disease by regulating autophagy and GSK-3β phosphorylation.2024Psychopharmacology
  11. Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature.2023Journal of cancer research and clinical oncology
  12. LncRNA TUG1 compromised neuronal mitophagy in cerebral ischemia/reperfusion injury by targeting sirtuin 1.2022Cell biology and toxicology
  13. Phloretin enhances autophagy by impairing AKT activation and inducing JNK-Beclin-1 pathway activation.2022Experimental and molecular pathology
  14. Adipose-derived stem cell-derived extracellular vesicles inhibit neuroblastoma growth by regulating GABBR1 activity through LINC00622-mediated transcription factor AR.2022Journal of leukocyte biology
  15. Identification of Key Genes Associated with Risk and Prognosis of Neuroblastoma.2022Journal of molecular neuroscience : MN
中文论文(未计入)1
  1. [Clinical analysis of 31 cases of esthesioneuroblastoma].2021Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
早期论文(2016–2020 年)14
  1. Long non-coding RNA SNHG7 promotes neuroblastoma progression through sponging miR-323a-5p and miR-342-5p.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis.2020IUBMB life
  3. LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases.2019Cancer biology & therapy
  4. LncRNA XIST facilitates cell growth, migration and invasion via modulating H3 histone methylation of DKK1 in neuroblastoma.2019Cell cycle (Georgetown, Tex.)
  5. miR-34a inhibits progression of neuroblastoma by targeting autophagy-related gene 5.2019European journal of pharmacology
  6. Upregulated lncRNA small nucleolar RNA host gene 1 promotes 1-methyl-4-phenylpyridinium ion-induced cytotoxicity and reactive oxygen species production through miR-15b-5p/GSK3β axis in human dopaminergic SH-SY5Y cells.2019Journal of cellular biochemistry
  7. XRCC1 gene polymorphisms and risk of neuroblastoma in Chinese children.2018Aging
  8. Advances in the Surgical Treatment of Neuroblastoma.2018Chinese medical journal
  9. Anisomycin prevents OGD-induced necroptosis by regulating the E3 ligase CHIP.2018Scientific reports
  10. Neuroprotective effects of α-melanocyte-stimulating hormone against the neurotoxicity of 1-methyl-4-phenylpyridinium.2017IUBMB life
  11. Honokiol triggers receptor‑interacting protein kinase 3‑mediated cell death of neuroblastoma cells by upregulating reactive oxygen species.2017Molecular medicine reports
  12. Truncated apolipoprotein C-I induces apoptosis in neuroblastoma by activating caspases in the extrinsic and intrinsic pathways.2017Oncology reports
  13. 2,2',4,4'-Tetrabromodiphenyl ether promotes human neuroblastoma SH-SY5Y cells migration via the GPER/PI3K/Akt signal pathway.2016Human & experimental toxicology
  14. Polymorphisms of glucose-regulated protein 78 and clinical relevance of neuroblastoma: Risk and prognosis.2016Journal of cancer research and therapeutics

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

郑州有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.9%。

牵头论文
15
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 6620232024: 3320242025: 002025

郑州有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛

  3. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  4. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

  5. 即将招募
    A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
    分期
    I/II期
    开始
    2025-02
    登记号
    NCT06799676

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层双抗与抗体药物CAR-T 与细胞治疗
论文中的科室病理/检验科肿瘤内科神经内科
牵头的论文15
  1. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.2024BMJ open免费全文
  2. Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization.2024Clinical and experimental medicine免费全文
  3. Quantitative Analysis of Whole-Body MRI for Accessing the Degree of Diffuse Infiltration Patterns and Identifying High Risk Cases of Newly Diagnosed Multiple Myeloma.2024Journal of magnetic resonance imaging : JMRI
  4. FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma.2023Cancer gene therapy
  5. A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.2023Cancer medicine免费全文
  6. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.2023Expert opinion on biological therapy
  7. Long non‑coding RNAs in multiple myeloma (Review).2023International journal of oncology免费全文
  8. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.2023Journal of hematology & oncology免费全文
  9. Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma.2023Scientific reports免费全文
  10. Evaluation of Diffuse Bone Marrow Infiltration Pattern in Monoclonal Plasma Cell Diseases by Quantitative Whole-body Magnetic Resonance Imaging.2022Academic radiology
  11. Chimeric antigen receptor T-cell therapy for multiple myeloma.2022Frontiers in immunology免费全文
  12. Differentiation of Diffuse Infiltration Pattern in Multiple Myeloma From Hyperplastic Hematopoietic Bone Marrow: Qualitative and Quantitative Analysis Using Whole-Body MRI.2022Journal of magnetic resonance imaging : JMRI
  13. Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma.2021Leukemia research
  14. Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment.2021Leukemia research
  15. Multiple myeloma with Echinococcus granulosus infection diagnosed by detection of oligoclonal bands: A case report.2021Medicine免费全文
中文论文(未计入)3
  1. [Expression of Interleukin-10 and Interleukin-15 in Patients with Multiple Myeloma and Its Clinical Significance].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Features and Prognosis of Multiple Myeloma Patients with Secondary Primary Malignancies].2023Zhongguo shi yan xue ye xue za zhiRCT
  3. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].2022Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Efficacy and Safety Evaluation of PD1-BCMA-CART状态不明NCT05308875牵头方(推断)不分期2024-03 启动
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  4. A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma即将招募NCT06799676研究中心I/II期2025-02 启动
  5. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  6. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  7. A Study of NINLARO® in Chinese Adults With Multiple Myeloma进行中,不再招募NCT05013190研究中心2021-10 启动
  8. Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies状态不明NCT03638206研究中心I/II期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

郑州有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
    分期
    IV期
    开始
    2023-09
    登记号
    NCT06339775

    年龄 未注明 至 65 岁(登记的条件)

    牵头:郑州大学第一附属医院郑州

  2. 正在招募
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    分期
    不分期
    开始
    2025-03
    登记号
    NCT06890065

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

  3. 正在招募
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    分期
    不分期
    开始
    2023-09
    登记号
    NCT06678282

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

  4. 正在招募
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    分期
    II期
    开始
    2022-01
    登记号
    NCT05334823

    年龄 3 岁 至 21 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、苏州、郑州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植费城染色体与遗传学

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 9 篇,占 2.2%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 2220232024: 1120242025: 112025

郑州有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07552506

    年龄 14 岁 至 50 岁;仅女性(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院;另有 3 家列出的医院为研究中心杭州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植儿童克隆演变与 PNH
论文中的科室儿科
牵头的论文9
  1. Protective factors, management and prognosis of mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia in children.2025Bone marrow transplantation
  2. Unbiased Single-Cell Sequencing of Hematopoietic and Immune Cells from Aplastic Anemia Reveals the Contributors of Hematopoiesis Failure and Dysfunctional Immune Regulation.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.2023Clinical and experimental medicine免费全文
  4. Analysis of Mean Corpuscular Volume and Red Cell Distribution Width in Patients with Aplastic Anemia.2023Hemoglobin
  5. Very severe aplastic anemia with papillary thyroid carcinoma: treatment with allo-HSCT-a case report and literature review.2022Annals of hematology
  6. MiR-150-5p regulate T cell activation in severe aplastic anemia by targeting Bach2.2021Cell and tissue research
  7. Acute arrest of hemopoiesis presenting as severe aplastic anemia: a retrospective analysis.2021Hematology (Amsterdam, Netherlands)
  8. Decreased bone marrow regulatory innate lymphoid cells show a distinctive miRNA profiling in aplastic anemia.2021Hematology (Amsterdam, Netherlands)
  9. Hypermethylation-mediated downregulation of long non-coding RNA MEG3 inhibits osteogenic differentiation of bone marrow mesenchymal stem cells and promotes pediatric aplastic anemia.2021International immunopharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin即将招募NCT07552506研究中心不分期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

郑州有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题EB病毒与感染诱因儿童淋巴瘤及肿瘤相关噬血
论文中的科室儿科耳鼻喉/头颈外科肿瘤内科
牵头的论文3
  1. Case Report: Two cases of chronic active Epstein-Barr virus disease presenting as refractory sinusitis.2025Frontiers in immunology免费全文
  2. Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection.2024Annals of hematology
  3. Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders.2024Hematology (Amsterdam, Netherlands)
中文论文(未计入)1
  1. [Analysis of clinical phenotype and genetic variant in a case of familial hemophagocytic lymphohistiocytosis type Ⅲ].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.状态不明NCT04999878牵头方(推断)IV期2021-05 启动
  2. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])正在招募NCT07208058研究中心III期2025-11 启动
PubMed 以外找到的论文(未计入)3
  1. Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study2025Blood会议摘要
  2. Cytokine Patterns for Secondary HLH: Experiences from a Single Center2024Blood会议摘要
  3. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)论文

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 1 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
论文中的科室儿科
中文论文(未计入)1
  1. [Genotypic and hematological characteristics of 83 β-thalassemia mutation carriers and patients from Henan Province].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 3 篇,占 1.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

郑州有 8 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06727669

    年龄未注明(登记的条件)

    牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科
牵头的论文3
  1. Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation.2022Biochemical and biophysical research communications
  2. Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China.2021Haemophilia : the official journal of the World Federation of Hemophilia
  3. FVIII inhibitor risk correlated with F8 gene variants in 296 unrelated male Chinese patients with haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
中文论文(未计入)1
  1. [Analysis of gene inversion in Hemophilia A by Nanopore sequencing].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)3
  1. Factor VIII mutation spectrum in haemophilia A patients in the population of Henan, China.2017Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  2. [Genetic analysis for a family affected with hemophilia type A due to a large deletion of F8 gene].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Detection and genetic counseling of F8 gene inversions for patients with severe hemophilia A].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Longitudinal Cohort of Thrombosis and Hemostasis Diseases正在招募NCT06727669研究中心2024-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

郑州有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06727669

    年龄未注明(登记的条件)

    牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科
牵头的论文1
  1. The features and risk factors of thrombotic thrombocytopenic purpura in systemic lupus erythematosus.2025Orphanet journal of rare diseases
中文论文(未计入)1
  1. [Clinical characteristics and outcome of 69 patients with thrombotic thrombocytopenic purpura].2022Zhonghua nei ke za zhi
早期论文(2016–2020 年)1
  1. Serum D-dimer as a potential new biomarker for prognosis in patients with thrombotic thrombocytopenic purpura.2020Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Longitudinal Cohort of Thrombosis and Hemostasis Diseases正在招募NCT06727669研究中心2024-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.3%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 2220222023: 0020232024: 1120242025: 332025

郑州有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗影像
论文中的科室神经内科儿科
牵头的论文11
  1. Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG.2025Frontiers in immunology免费全文
  3. Biomarkers for diagnosis and prognosis of myelin oligodendrocyte glycoprotein antibody-associated disease - review article.2025Frontiers in immunology免费全文
  4. Renal dysfunction in AQP4 NMOSD and MS; a potential predictor of relapse and prognosis.2024Clinical immunology (Orlando, Fla.)
  5. Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders.2022Brain and behavior免费全文
  6. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.2022Journal of neurology
  7. Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study.2021BMC neurology免费全文
  8. Serum Immunoglobulin G Level and Neutrophils to Lymphocytes Ratio Associated with the Prognosis of Neuromyelitis Optica Spectrum Disorder.2021Current neurovascular research
  9. High Level of Serum and Cerebrospinal Fluid of Heparan Sulfate and Hyaluronic Acid Might Be a Biomarker of Severity of Neuromyelitis Optica.2021Frontiers in immunology免费全文
  10. Association of Circulating Follicular Helper T Cells and Serum CXCL13 With Neuromyelitis Optica Spectrum Disorders.2021Frontiers in immunology免费全文
  11. Impaired Meningeal Lymphatic Flow in NMOSD Patients With Acute Attack.2021Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  2. A Study of RD06-04 in Patients With Active Autoimmune Diseases已撤回NCT06548620研究中心早期I期2024-08 启动
  3. An Open Label Study of the Effects of SHR1459 in NMOSDs Patients已完成NCT04670770研究中心II期2021-01 启动
PubMed 以外找到的论文(未计入)8
  1. A Real-world Study of Inebilizumab for Neuromyelitis Optica Spectrum Disorders (P9-1.008)2025Neurology论文
  2. Association of Roquin-1 and Tfh cells with Clinical Characteristic in Neuromyelitis Optica (P11-8.003)2025Neurology论文
  3. MALT1 Scaffold and Proteolytic Activity Regulate Tfh Cell Differentiation in the Progression of Neuromyelitis Optica (S38.002)2025Neurology论文
  4. Potential Correlation Between the Cuprotosis-Related Genes and Acute-Remitting Course in Neuromyelitis Optica Spectrum Disorder (P12-8.004)2025Neurology论文
  5. Progress on single-cell sequencing technology in central nervous system autoimmune diseases2025DOAJ (DOAJ: Directory of Open Access Journals)论文
  6. Loss of Roquin-1 Enhances CXCR5+PD-1+ Tfh Cell Differentiation by Interfering with Ampkfunction to Enhance Glycolysis in AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorders2024SSRN Electronic Journal预印本
  7. Loss of Roquin-1 enhances CXCR5+PD-1+Tfh cell differentiation by interfere AMPK function to enhance glycolysis in Neuromyelitis Optica2024Research Square预印本
  8. Is low threshold of B cells an obligatory monitoring indicator of repeated RTX infusion in the treatment of Neuromyelitis Optica spectrum disorder? – A report of two cases2021Neuroimmunology Reports论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

郑州有 3 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    分期
    I期
    开始
    2025-09
    登记号
    NCT07215650

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、天津、太原、广州、成都、贵阳、郑州、长春

  2. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断常规免疫治疗
论文中的科室神经内科
牵头的论文4
  1. The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.2025Muscle & nerve
  2. Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Myasthenia Gravis and Ischemic Stroke: A Bidirectional Mendelian Randomization Study.2023Current neurovascular research
  4. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.2022BMC neurology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)正在招募NCT07215650研究中心I期2025-09 启动
  2. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  3. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 2.8%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 4420232024: 3320242025: 222025

郑州有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

  2. 正在招募
    Registry of Multicenter Brain-Heart Comorbidity in China
    分期
    未注明
    开始
    2012-01
    登记号
    NCT05961748

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与脑血流中风与出血血管重建手术
论文中的科室神经外科神经内科儿科影像/核医学科
牵头的论文10
  1. Clinical characteristics and potential pathology of Moyamoya disease combined with psychiatric disorders in Chinese population - A cross-sectional study.2025Journal of affective disorders
  2. Development and validation of nomograms for aneurysm rupture risk and prognosis in Moyamoya disease with intracranial aneurysms.2025Scientific reports免费全文
  3. Moyamoya syndrome secondary to hereditary spherocytosis: A case report.2024Asian journal of surgery
  4. Proteomics and digital subtraction angiography approaches reveal CDH18 as a potential target for therapy of moyamoya disease.2024Biology direct免费全文
  5. Cerebral hemodynamic plasticity related to potential compensatory self-recirculation network in Moyamoya disease: an observational study.2024Scientific reports免费全文
  6. Follow-up outcomes of different bypass surgical modalities for adults with ischaemic-type moyamoya disease.2023British journal of neurosurgery
  7. A Retrospective Study on Clinical Features of Childhood Moyamoya Disease.2023Pediatric neurology
  8. Risk factors for wound healing complications after revascularization for MMD with complete Y-shaped incision.2023Scientific reports免费全文
  9. Analysis of Clinical Characteristic and Risk Factors for Short-Term Prognosis of Moyamoya Disease with Intraventricular Hemorrhage in Adults.2023World neurosurgery
  10. Clinical features of and risk factors for intracranial aneurysms associated with moyamoya disease.2021International journal of stroke : official journal of the International Stroke Society
中文论文(未计入)1
  1. [Clinical analysis of 15 pregnant women complicated with moyamoya disease].2023Zhonghua fu chan ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome正在招募NCT07894107研究中心2026-08 启动
  2. Registry of Multicenter Brain-Heart Comorbidity in China正在招募NCT05961748研究中心2012-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

郑州有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)治疗(螯合剂、锌剂)儿童
论文中的科室神经内科
牵头的论文1
  1. Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.2021Clinics and research in hepatology and gastroenterology
中文论文(未计入)1
  1. [Genotype-phenotype relationship and genetics study of 115 cases with Wilson's disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 9 篇,占 3.4%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 0020232024: 1120242025: 222025

郑州有 6 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
    分期
    III期
    开始
    2024-11
    登记号
    NCT06867991

    年龄 12 岁 至 未注明(登记的条件)

    牵头:常州市第一人民医院;另有 1 家列出的医院为研究中心常州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科
牵头的论文9
  1. Clinical characteristics and treatment of patients with overlapping MOG and anti-NMDAR encephalitis.2025BMC neurology
  2. The gut-brain axis: potential reshaping the future of anti-NMDAR encephalitis treatment.2025Frontiers in immunology
  3. Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Relapse factors of patients of anti-N-methyl-D-aspartate receptor encephalitis.2022Acta neurologica Scandinavica
  5. Brain magnetic resonance imaging predictors in anti-N-methyl-D-aspartate receptor encephalitis.2022Annals of clinical and translational neurology
  6. Neutrophil Percentage-to-Albumin Ratio: A Good Parameter for the Evaluation of the Severity of Anti-NMDAR Encephalitis at Admission and Prediction of Short-Term Prognosis.2022Frontiers in immunology
  7. Clinical and Radiological Characteristics of Children and Adults With First-Attack Myelin Oligodendrocyte Glycoprotein Antibody Disease and Analysis of Risk Factors for Predicting the Severity at Disease Onset in Central China.2021Frontiers in immunology
  8. Influential factors and predictors of anti-N-methyl-D-aspartate receptor encephalitis associated with severity at admission.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Emerging role of free triiodothyronine in patients with anti-N-methyl-D-aspartate receptor encephalitis.2021Scientific reports
早期论文(2016–2020 年)3
  1. A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies.2020BMC neurology
  2. Anti-N-methyl-D-aspartate receptor encephalitis: a prospective study focused on cerebrospinal fluid and clinical symptoms.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. [Clinical analysis of anti-NMDA receptor encephalitis complicated by paroxysmal sympathetic hyperactivity].2016Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis正在招募NCT06867991研究中心III期2024-11 启动
  2. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies即将招募NCT07858175研究中心2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 2 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

郑州有 1 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
牵头的论文1
  1. Multiple hepatic alveolar echinococcosis infestation.2024Asian journal of surgery

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 12 篇,占 1.2%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 2220242025: 332025

郑州有 12 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文12
  1. Inhalable nanosystem promote in situ packaging of IL-11 antisense oligonucleotides into macrophage-derived vesicles for idiopathic pulmonary fibrosis.2026Journal of controlled release : official journal of the Controlled Release Society
  2. Resveratrol improves idiopathic pulmonary fibrosis by targeting IKZF3.2026The Journal of nutritional biochemistry
  3. Single Cell RNA-Seq Identifies Cell Subpopulations Contributing to Idiopathic Pulmonary Fibrosis in Humans.2025Journal of cellular and molecular medicine
  4. The role of oxidative stress-related genes in idiopathic pulmonary fibrosis.2025Scientific reports
  5. Causal Effects Between Genetically Determined Human Serum Metabolite Levels on the Risk of Idiopathic Pulmonary Fibrosis: A Mendelian Randomization Study.2025The clinical respiratory journal
  6. ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target.2024Journal of translational medicine
  7. SULF1 expression is increased and promotes fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis.2024Journal of translational medicine
  8. Multicenter Population Pharmacokinetics and Exposure-Efficacy Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.2023Clinical pharmacokinetics
  9. Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma.2023Pulmonary pharmacology & therapeutics
  10. Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway.2022International immunopharmacology
  11. Nitrative inactivation of thioredoxin-1 loses its protective effect in bleomycin-induced pulmonary fibrosis.2022International immunopharmacology
  12. Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials.2021BMJ open
中文论文(未计入)1
  1. [Pulmonary artery stenosis after single lung transplantation: a case report and literature review].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
早期论文(2016–2020 年)5
  1. CircRNA TADA2A relieves idiopathic pulmonary fibrosis by inhibiting proliferation and activation of fibroblasts.2020Cell death & disease
  2. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].2020Zhonghua yi xue za zhi
  3. Knockdown of Long Noncoding RNA H19 Represses the Progress of Pulmonary Fibrosis through the Transforming Growth Factor β/Smad3 Pathway by Regulating MicroRNA 140.2019Molecular and cellular biology
  4. S100A4+ Macrophages Are Necessary for Pulmonary Fibrosis by Activating Lung Fibroblasts.2018Frontiers in immunology
  5. Role of thioredoxin nitration in bleomycin-induced pulmonary fibrosis in rats.2016Canadian journal of physiology and pharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  3. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  4. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04594707研究中心III期2021-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年没有牵头肺淋巴管平滑肌瘤病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 1 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.6%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 0020232024: 1120242025: 002025

郑州有 3 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
    分期
    I期
    开始
    2024-11
    登记号
    NCT06671236

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科耳鼻喉/头颈外科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Identification of two novel SMN1 point mutations associated with a very severe SMA-I phenotype.2020European journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 2 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Pseudo-dominant inheritance of a novel double GLA mutation associated with Fabry disease mimicking familial episodic pain.2016American journal of medical genetics. Part A
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease状态不明NCT06114329研究中心II期2023-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年没有牵头庞贝病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 1 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug进行中,不再招募NCT05793307研究中心I/II期2023-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.8%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 0020242025: 222025

郑州有 5 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
牵头的论文6
  1. Unexpected Findings of Duchenne Muscular Dystrophy in Prenatal Screening of Chromosome Abnormality Based on Cell-Free Fetal DNA.2025American journal of perinatology
  2. GsMTx4-blocked PIEZO1 channel promotes myogenic differentiation and alleviates myofiber damage in Duchenne muscular dystrophy.2025Skeletal muscle
  3. Prenatal diagnosis of 1408 foetuses at risk of DMD/BMD by MLPA and Sanger sequencing combined with STR linkage analysis.2023BMC medical genomics
  4. Noninvasive prenatal testing of Duchenne muscular dystrophy in a twin gestation.2022Prenatal diagnosis
  5. Noninvasive prenatal diagnosis of duchenne muscular dystrophy in five Chinese families based on relative mutation dosage approach.2021BMC medical genomics
  6. DMD/BMD prenatal diagnosis and treatment expectation in a single centre in China for 15 years.2021BMC medical genomics
中文论文(未计入)4
  1. [Analysis of DMD gene variants in a single center].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Analysis of results of prenatal diagnosis for 67 pedigrees affected with Duchenne muscular dystrophy in the central plain region of China].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Diagnosis of a patient with adjacent gene deletion syndrome with DMD complete deletion type of Duchenne muscular dystrophy].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  4. [Variant analysis and therapeutic prospect for Chinese pedigrees affected with Duchenne/Becker muscular dystrophy from a single center over the past 15 years].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)7
  1. Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy.2019BMC medical genetics
  2. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.2019Human gene therapy methods
  3. [Application of next-generation sequencing in the molecular diagnosis of Duchenne muscular dystrophy].2019Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  4. [Two cases of rare diseases with abnormalities of X chromosome].2019Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  5. Generation of ZZUi008-A, a transgene-free, induced pluripotent stem cell line derived from chorionic villi cells of a fetus with Duchenne muscular dystrophy.2018Stem cell research
  6. [Mutation analysis of 81 cases with Duchenne/Becker muscular dystrophy].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  7. [Mutation screening of 433 families with Duchenne/Becker muscular dystrophy].2016Zhonghua yi xue za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 9 篇,占 3.7%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 3320232024: 2220242025: 002025

郑州有 2 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 2 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科
中文论文(未计入)5
  1. [Genetic testing and prenatal diagnosis for two Chinese pedigrees affected with Alport syndrome due to variants of COL4A5 gene].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  2. [Clinical and genetic analysis of a child with X-linked dominant Alport syndrome].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Genetic analysis of a patient with Alport syndrome due to compound heterozygous variants of COL4A4 gene].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  4. [Analysis of two Chinese pedigrees affected with Alport syndrome due to novel variants of COL4A5 gene].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  5. [Genetic and clinical analysis of a pedigree affected with X-linked dominant Alport syndrome due to a novel variant of COL4A5 gene].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)1
  1. Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique.2019Molecular genetics & genomic medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 35 篇,占 4.8%。

牵头论文
35
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 9920222023: 5520232024: 7720242025: 662025

郑州有 3 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科儿科病理/检验科
牵头的论文35
  1. The association between fractalkine/CX3CR1 axis with IgA vasculitis and nephritis.2026Pediatric research
  2. Yeast Cell Wall-Mediated Ileal Targeted Delivery System for IgA Nepharopathy Therapy.2025ACS biomaterials science & engineering
  3. The role of innate lymphoid cells in kidney disease.2025Cytokine & growth factor reviews
  4. Noninvasive prediction of T-score in IgA nephropathy using machine learning within the Oxford classification system.2025Frontiers in endocrinology
  5. Efficacy of methylprednisolone pulse therapy in Chinese children with IgA vasculitis-associated nephritis (IgAVN).2025Journal of nephrology
  6. Gut microbiota as a predictive tool for outcomes in IgA nephropathy.2025Renal failure
  7. Single nucleus RNA-seq reveals the process from onset to chronic kidney disease in IgA nephropathy.2025Scientific reports
  8. Differentiated metabolomic profiling reveals plasma amino acid signatures for primary glomerular disease.2024Amino acids
  9. External validation of the pediatric International IgA Nephropathy Prediction Tool in a central China cohort.2024Clinical and experimental nephrology
  10. Clinical features and prognosis of patients with anti-GBM disease combined with mesangial IgA deposition.2024Frontiers in immunology
  11. Genome-wide analysis of long noncoding RNAs as cis-acting regulators of transcription factor-encoding genes in IgA nephropathy.2024PloS one
  12. The prognostic value of the systemic immune inflammation index in patients with IgA nephropathy.2024Renal failure
  13. Novel immune cross-talk between inflammatory bowel disease and IgA nephropathy.2024Renal failure
  14. The transcription factor HMGB2 indirectly regulates APRIL expression and Gd-IgA1 production in patients with IgA nephropathy.2024Renal failure
  15. Mild mesangial proliferative IgA nephropathy with and without minimal change disease.2023Clinical and experimental medicine
  16. Telitacicept for autoimmune nephropathy.2023Frontiers in immunology
  17. Established the first clinical prediction model regarding the risk of hyperuricemia in adult IgA nephropathy.2023International urology and nephrology
  18. Role of abnormal glycosylated IgA1 and interstitial transformation of glomerular endothelial cells in the development and progression of IgA nephropathy.2023Italian journal of pediatrics
  19. Predictive prognostic value of glomerular C3 deposition in IgA nephropathy.2023Journal of nephrology
  20. Renal Megalin mRNA Downregulation Is Associated with CKD Progression in IgA Nephropathy.2022American journal of nephrology
  21. IgA nephropathy with acute kidney disease: Characteristics, prognosis, and causes.2022European journal of internal medicine
  22. Development and validation of diagnostic models for immunoglobulin A nephropathy based on gut microbes.2022Frontiers in cellular and infection microbiology
  23. Hyperuricemia aggravates the progression of IgA nephropathy.2022International urology and nephrology
  24. Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy.2022International urology and nephrology
  25. The predictive value of Oxford MEST-C classification to immunosuppressive therapy of IgA nephropathy.2022International urology and nephrology
  26. Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis.2022International urology and nephrology
  27. The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov.2022Renal failure
  28. ICAM-1 related long noncoding RNA is associated with progression of IgA nephropathy and fibrotic changes in proximal tubular cells.2022Scientific reports
  29. Preliminary study on the application of renal ultrasonography radiomics in the classification of glomerulopathy.2021BMC medical imaging
  30. Overlapping obesity-related glomerulopathy and immunoglobulin A nephropathy: clinical and pathologic characteristics and prognosis.2021Clinical and experimental nephrology
  31. Elevated Serum Chloride Levels Contribute to a Poor Prognosis in Patients with IgA Nephropathy.2021Journal of immunology research
  32. Role of Human Mesangial-Tubular Crosstalk in Secretory IgA-Induced IgA Nephropathy.2021Kidney & blood pressure research
  33. Elevated Endostatin Expression Is Regulated by the pIgA Immune Complex and Associated with Disease Severity of IgA Nephropathy.2021Kidney & blood pressure research
  34. Normotensive and hypertensive Immunoglobulin a nephropathy with ischemic renal injury: clinicopathological characteristics and prognosis.2021Renal failure
  35. MicroRNAs in IgA nephropathy.2021Renal failure
早期论文(2016–2020 年)17
  1. External Validation of the International IgA Nephropathy Prediction Tool.2020Clinical journal of the American Society of Nephrology : CJASN
  2. The TLR4-MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy.2020Journal of nephrology
  3. The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy.2020PloS one
  4. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases.2020Scientific reports
  5. A non-invasive diagnostic model of immunoglobulin A nephropathy and serological markers for evaluating disease severity.2019Chinese medical journal
  6. Elevated hsa-miR-590-3p expression down-regulates HMGB2 expression and contributes to the severity of IgA nephropathy.2019Journal of cellular and molecular medicine
  7. High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy.2019Nephrology (Carlton, Vic.)
  8. [Clinical effect of tacrolimus combined with glucocorticoid in the treatment of IgA nephropathy in children].2019Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  9. Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy.2018American journal of physiology. Renal physiology
  10. Renal miR-148b is associated with megalin down-regulation in IgA nephropathy.2018Bioscience reports
  11. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.2018Journal of the American Society of Nephrology : JASN
  12. Intrarenal Arterial Lesions Are Associated with Higher Blood Pressure, Reduced Renal Function and Poorer Renal Outcomes in Patients with IgA Nephropathy.2018Kidney & blood pressure research
  13. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.2017Clinical and experimental immunology
  14. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis.2017International urology and nephrology
  15. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.2017PloS one
  16. Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases.2016Diagnostic pathology
  17. MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients.2016Experimental cell research
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  2. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 3 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
中文论文(未计入)2
  1. [Analysis of LRP5 gene variants in a Chinese pedigree affected with Osteoporosis-pseudoglioma syndrome].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  2. [Preimplantation genetic testing for a couple where the husband is affected by osteogenesis imperfecta combined with balanced translocation using karyomapping technique].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)3
  1. [Analysis of COL1A1 gene variants in five Chinese pedigrees affected with osteogenesis imperfecta].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  2. Solanum muricatum Ameliorates the Symptoms of Osteogenesis Imperfecta In Vivo.2019Journal of food science
  3. [Mutational analysis and prenatal diagnosis of COL1A1 and COL1A2 genes in four Chinese families affected with osteogenesis imperfecta].2017Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

郑州有 2 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 2 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Analysis of a case with Mowat-Wilson syndrome due to nonsense variant of ZEB2 gene].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

郑州有 2 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

郑州大学第一附属医院

First Affiliated Hospital of Zhengzhou University

郑州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
first Affiliated Hospital of Zhengzhou University; Zhengzhou University First Affiliated Hospital

提出更正下载数据